Stockwinners Market Radar for December 06, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:21 EST Cathie Wood's ARK Investment bought 254.6K shares of XPeng on Monday

20:20 EST Cathie Wood's ARK Investment bought 231K shares of Twitter on Monday

19:07 EST 17 Education & Technology to cease tutoring services - The company states: "17 Education & Technology Group provided business updates following the recent regulatory developments relating to after-school tutoring services, including the Opinions on Further Alleviating the Burden of Homework and After-School Tutoring on Students in Compulsory Education, published in July 2021 by the General Office of the CPC Central Committee and the General Office of the State Council, also known as the double reduction policy , and the related implementation rules, regulations and measures promulgated by competent authorities. In compliance with the Opinion and applicable rules, regulations and measures, the Company plans to cease offering tutoring services related to academic subjects to students from kindergarten through the last year of senior high school in mainland China by the end of 2021. The Company expects that the cessation will have a substantial adverse impact on the Company's revenues for the fiscal year ending December 31, 2021 and subsequent periods. In the fiscal years ended December 31, 2019 and 2020, revenues from K-12 Academic AST Services accounted for a substantial majority of the Company's total revenues for each fiscal year. The Company will continue to explore opportunities in educational products and services that are not related to K-12 Academic AST Services in accordance with relevant rules and regulations."

18:13 EST U.S. Representative Devin Nunes to join Trump Media as CEO - Trump Media & Technology Group, which has previously announced a deal to go public through a merger with special purpose acquisition company Digital World Acquisition Corp., announced that Congressman Devin G. Nunes has been selected to join the company as Chief Executive Officer. Nunes is currently a sitting U.S. House Representative, representing California's 22nd congressional district, and formerly the Chair of the House Intelligence Committee. Nunes will be leaving the U.S. House of Representatives and will begin his new role as Chief Executive Officer of TMTG in January 2022. President Donald J. Trump, Chairman of TMTG, commented, "Congressman Devin Nunes is a fighter and a leader. He will make an excellent CEO of TMTG. Devin understands that we must stop the liberal media and Big Tech from destroying the freedoms that make America great. America is ready for TRUTH Social and the end to censorship and political discrimination." Reference Link

17:42 EST Coupa Software sees Q4 calculated billings $290M - Says calculated billings guidance backs out the one-time opening deferred revenue benefit of $14.8M for Lamasoft from Q4 of last year. Says after adjustment, the resulting organic calculated billings guide would be in the mid-teens percentage wise up from high-single digits last quarter. Says since fewer days in Q1, steady state subscription revenues are lower in Q1 compared to Q4. Comments taken from Q3 earnings conference call.

17:25 EST Point72 Asset Management takes 5.4% passive stake in Krystal Biotech - Point72 Asset Management disclosed a 5.4% stake in Krystal Biotech, which represents over 1.34M shares. The filing does not allow for activism.

17:24 EST Glacier Bancorp announces transfer of common stock listing to NYSE - Glacier Bancorp announced that it is transferring the listing of its common stock to the New York Stock Exchange from The NASDAQ Global Select Market. Glacier Bancorp's common stock will begin trading on the NYSE on December 17, 2021 under its current ticker symbol of 'GBCI'. Glacier Bancorp will continue to trade its common stock on NASDAQ until the close of the market on December 16, 2021. "Glacier Bancorp is pleased to join the NYSE alongside many of the world's most well-established and regarded companies," said Randy Chesler, President and CEO of Glacier Bancorp. "This move is part of our strategic evolution as we continue to focus on generating long-term value for our shareholders. We are grateful for our past partnership with NASDAQ and look forward to our future with the NYSE."

17:21 EST Pfizer EVP Mackenzie sells 41,360 common shares - In a regulatory filing, Pfizer executive VP Alexander Mackenzie disclosed the sale of 41,360 common shares of the company on December 2 at a price of $54.26 per share.

17:03 EST Callaway Golf CFO buys $386.9K in common stock - In a regulatory filing, Callaway Golf disclosed that its CFO Brian Lynch bought 15K shares of common stock in a total transaction size of $386.9K on December 2nd, boosting his stake by 228%. Shares of Callaway Golf are up 1.7% at $27.06 after-hours.

16:54 EST Aris Water Solutions initiates quarterly dividend of 7c per share - The dividend will be paid on January 27, 2022 to holders of record of the Company's Class A common stock as of the close of business on January 6, 2022.

16:31 EST Asur reports November 2021 passenger traffic up 7.2% vs November 2019 - Asur announced passenger traffic for November 2021 reached a total of 4.9M passengers, 7.2% above the levels reported in November 2019, reflecting a continued overall recovery in travel demand and the rollout of vaccination campaigns in the US and gradual advances in Mexico, despite restrictions and requirements in certain countries of the world to contain the spread of the virus. When compared to pre-pandemic levels of November 2019, passenger traffic increased 5.2% in Mexico and 6.9% in Puerto Rico and 12.8% Colombia. Passenger traffic growth in Mexico and Colombia was driven by both domestic and international traffic, while domestic traffic growth more than offset passenger lower international traffic in Puerto Rico during the period. This announcement reflects comparisons between November 1 through November 30, 2021, from November 1 through November 30, 2020 and November 1 through November 30, 2019. Transit and general aviation passengers are excluded for Mexico and Colombia.

16:23 EST Shineco in securities purchase pact with GHS Investments, with proceeds $2M - Shineco announced that it has entered into a securities purchase agreement for the sale of Gross Proceeds $2.0M of its registered common stock at a price of $6.8546 per share with GHS Investments a leading private investment and management group providing financial solutions for high potential small cap enterprises. The Company intends to use the net proceeds from this offering to acquire certain biotech research companies as well as for working capital and general corporate purposes at the sole discretion of the Company. This offering is being made pursuant to an effective shelf registration statement on Form S-3, as amended which was subsequently declared effective by the U.S. Securities and Exchange Commission on June 23

16:21 EST Coupa Software drops 8% to $160.00 after reporting Q3 results, FY22 guidance

16:20 EST MongoDB jumps 17% to $503.03 after Q3 results, guidance top estimates

16:20 EST Sumo Logic appoints Stewart Grierson as CFO - Sumo Logic announced the appointment of Stewart Grierson as CFO, effective December 13. As a member of the company's senior executive team, Stewart will focus on operational efficiency, financial management, and investor relations. Stewart has been leading finance and operations teams of public and private technology companies for more than 25 years. He joins Sumo Logic from Delphix, where he served as CFO.

16:19 EST MongoDB reports Q3 subscription revenue $217.9M, up 51% y/y - Q3 services revenue was $9M, an increase of 35% year-over-year.

16:16 EST Newpark Resources announces non-binding MOU for JV in Saudi Arabia - Newpark Resources announced that the company's Fluids Systems operating segment and Industrialization and Energy Services Company, based in Dhahran, Saudi Arabia, have entered into a non-binding preliminary Memorandum of Understanding. Through this MOU, both companies intend to establish a joint venture company providing oilfield chemicals and other high performance related products and services including, as the core business, drilling and reservoir fluids, industrial minerals, and related services in the Kingdom of Saudi Arabia with further potential future expansion into other strategic territories. Newpark will provide technical and other support to the joint venture, with a mandate to increase specialty chemicals research and development as well as manufacturing capabilities in Saudi Arabia, leveraging TAQA's existing product and service footprint.

16:13 EST Blueprint Medicines: Nature Medicine publishes results from AYVAKIT studies - Blueprint Medicines announced two Nature Medicine publications on the registration-enabling EXPLORER and PATHFINDER trials of AYVAKIT, highlighting its robust efficacy and safety datasets in advanced systemic mastocytosis. The publications feature overall response, patient-reported outcomes and survival data, which reinforce the durable activity of AYVAKIT. Additional new analyses underscore the treatment's impact regardless of patient subgroup or disease pathology. Based on these data, AYVAKIT was approved by the U.S. FDA for the treatment of adults with advanced SM in June 2021.

16:09 EST GoHealth names Vance Johnston as CFO - GoHealth announced that Vance Johnston will join the company as CFO on December 7. As previously announced, Travis Matthiesen, the company's current CFO, will transition to the role of Chief Transformation Officer and will work closely with Johnston to ensure a smooth transition. Prior to joining GoHealth, Johnston held public company CFO positions at IAA, Inc., a global technology and auto services company; SP Plus Corporation, a business services company; and Furniture Brands International, Inc., a consumer goods, manufacturing and retail company, along with several other senior level strategy, finance and operational roles in various industries.

16:08 EST Acadia Pharmaceuticals' trofinetide demonstrated improvement in Rett Syndrome - The company states: "Acadia Pharmaceuticals announced positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. On the Rett Syndrome Behaviour Questionnaire, change from baseline to week 12 was -5.1 vs. -1.7. The Clinical Global Impression-Improvement score at week 12 was 3.5 vs. 3.8. Additionally, trofinetide demonstrated a statistically significant separation over placebo on the key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist-Social composite score change from baseline to week 12 was -0.1 vs. -1.1. Study treatment discontinuation rates related to treatment emergent adverse events were 17.2% in the trofinetide group as compared to 2.1% in the placebo group. The most common adverse events were diarrhea, of which 97.3% in the trofinetide arm were characterized as mild-to-moderate, and vomiting, of which 96% in the trofinetide arm were characterized as mild-to-moderate. Serious adverse events were observed in 3.2% of study participants in both the trofinetide and placebo groups. Patients completing the Lavender study had the opportunity to continue to receive trofinetide in the open-label Lilac and Lilac-2 extension studies. More than 95% of participants who completed the Lavender study elected to roll-over to the Lilac open-label extension study."

16:03 EST Taysha Gene Therapies submits positive preclinical data abstract for TSHA-105 - Taysha Gene Therapies "announced a late-breaking abstract and poster presentation by Dr. Rachel Bailey, Assistant Professor at UT Southwestern Medical Center on positive preclinical data for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy at the American Epilepsy Society Annual Meeting on December 6th 2021. "Currently there are no treatments for SLC13A5 deficiency that target the underlying cause of disease. In knockout mouse models of SLC13A5 deficiency, treatment with TSHA-105 resulted in normalized citrate levels, reduced seizure activity and improved survival regardless of age. We are highly encouraged by the positive therapeutic response and absence of toxicity in these preclinical models and look forward to further exploring the possible utility of TSHA-105 as a treatment for SLC13A5 deficiency," said Rachel M. Bailey, Ph.D., Assistant Professor with the Center for Alzheimer's and Neurodegenerative Diseases and Pediatrics at UT Southwestern.

16:01 EST CGI Inc. to acquire Unico, terms not disclosed - CGI announces that its subsidiary, CGI Technology and Solutions Australia Pty Limited, has signed an agreement to acquire Unico, a technology consultancy and systems integrator based in Melbourne, Australia. The transaction is subject to approval by Australia's Foreign Investment Review Board and is expected to close sometime next quarter. The acquisition will grow CGI's footprint in Australia, with a focus on the Melbourne metro market, and in key industry sectors, including communications, government, utilities and financial services.

15:12 EST CareTrust REIT up 6% after Bloomberg says company weighing possible sale

14:41 EST Toyota confirms plan to build $1.29B EV battery plant in North Carolina - Governor Roy Cooper of North Carolina and Mayor Filmore York of Liberty, North Carolina, joined Toyota Motor North America's leaders to announce Greensboro-Randolph Megasite has been chosen as the location for Toyota's new $1.29B automotive battery manufacturing plant, to be named, Toyota Battery Manufacturing, North Carolina. When it comes online in 2025, TBMNC will have four production lines, each capable of delivering enough lithium-ion batteries for 200,000 vehicles-with the intention to expand to at least six production lines for a combined total of up to 1.2M vehicles per year. The $1.29B investment made by Toyota and Toyota Tsusho is partially funded from a total investment of approximately $3.4B previously announced on October 18, and is expected to create 1,750 new American jobs. "The future of mobility is electrification and the Greensboro-Randolph Megasite is the ideal location to make that future a reality," said Ted Ogawa, CEO of Toyota Motor North America. "North Carolina offers the right conditions for this investment, including the infrastructure, high-quality education system, access to a diverse and skilled workforce, and a welcoming environment for doing business. Today marks the beginning of a mutually beneficial partnership with the Tar Heel state as we embark on our journey to achieve carbon neutrality and provide mobility for all."

13:40 EST Reata plunges after FDA releases briefing docs for Bardoxolone meeting - Shares of Reata Pharmaceuticals are down $29.96, or 38%, to $48.74 in Monday afternoon trading after the FDA earlier this morning had posted the briefing documents for the panel members of the Advisory Committee meeting being called on December 8 to discuss whether the results of the CARDINAL Phase 3 study demonstrate that bardoxolone, proposed trade name IMBARKYD, slows the loss of kidney function in patients with Alport Syndrome and whether it is reasonable to conclude, based on the available data, that bardoxolone, when used chronically, will reduce the risk of progression to kidney failure in patients with this disease. In the documents, FDA staff stated: "The FDA review team recognizes that there is significant unmet need for treatments that can slow the loss of kidney function in patients with AS and reduce the risk of progression to kidney failure. The FDA review team also recognizes that the law allows for regulatory flexibility in determining what constitutes substantial evidence of effectiveness. However, for the reasons discussed above, the FDA review team does not believe the submitted data demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with AS and reducing the risk of progression to kidney failure. The FDA is convening this Advisory Committee Meeting to discuss these issues further." Reference Link

13:32 EST Fastly 'stands by' revenue guidance, says pricing pressure declined in 2021 - "We're happy with how the quarter is progressing and we stand by our existing revenue guidance. Today, a big part of our business is usage-based and there will always be some inherent volatility and our revenue guidance will continue to reflect that inherent volatility in our business and the outlook we have high confidence in. [...] We actually saw a deceleration of pricing pressure in 2021. Pricing declines in '21 were actually lower than what we saw in '19 and '20," Ron Kisling, CFO of Fastly, said during the Raymond James Technology Investors Conference.

12:46 EST Outerbridge Capital says ISS supports case for change at Comtech - Outerbridge Capital Management, a beneficial owner of approximately 4.9% of Comtech Telecommunications Corp.'s outstanding shares of common stock, announced that proxy advisory firm Institutional Shareholder Services has recommended that shareholders vote on the WHITE proxy card for Outerbridge director candidate Sidney "Sid" Fuchs for election to the Comtech (CMTL) Board of Directors at the upcoming 2021 Annual Meeting of Stockholders scheduled for December 17, 2021. Outerbridge strongly urges shareholders to vote on the WHITE proxy card to elect BOTH of its nominees - Wendi Carpenter and Sid Fuchs. In its report, ISS comments on the company's chronic underperformance under Comtech's current Board and management and the need for change, particularly given the recent offer made by Acacia Research Corp. (ACTG) to acquire the company for $790M in cash: "Considering the company's subpar performance, the board's unconvincing self-refresh, and the seemingly defensive nature of the White Hat investment, the dissident has made a compelling case that the addition of an independent outside director not sourced by the legacy board would be comforting to shareholders, particularly to ensure a comprehensive evaluation of the company's strategy and the pending offer from Acacia." ISS also said: "... Acacia appears to be a credible potential buyer, with approximately $605 million of cash and marketable securities as of Sept. 30, 2021, a history of executing multiple deals, and the backing of Starboard Value. As such, the lack of a more fulsome response to Acacia's approach over a month since the offer was made appears to validate the dissident's concern that the board may not intend to meaningfully engage with Acacia."

12:17 EST Digital Turbine expands Telefonica partnership - Digital Turbine (APPS) announced it's expanding their strategic partnership with Telefonica (TEF). The agreement spans European and Latin American markets and adds new products such as Wizard, Notifications and SingleTap that deliver best-in-class app recommendation experiences to their subscribers. Integration of Digital Turbine's Ignite On-Device Platform is already underway across the regions with the first launch expected in Q4 2021 by Movistar Chile.

12:16 EST Adicet Bio trading resumes

12:11 EST Adicet Bio trading halted, volatility trading pause

12:03 EST Stagwell appoints Robyn Freye as CGO, Alexis Williams as CBO - Stagwell announced several senior appointments that will help position the Company for accelerated global growth and talent acquisition as it enters 2022. Key appointments include: Robyn Freye has been named SVP, Chief Growth Officer, North America to lead strategic growth initiatives for the North America market and build a robust client growth strategy across network. At Stagwell, Freye has been instrumental in attracting key client engagements to the global roster, including Google, Uber and Expedia. Alexis Williams has been named SVP, Chief Brand Officer, North America and will lead brand marketing efforts collaborating with Stagwell's global and growth teams. Williams was instrumental in the development of Stagwell Inc.'s brand amid the combination of MDC Partners Inc. and Stagwell Marketing Group LLC. and serves as an advisor to key network communications clients. Nate Napier has been named SVP, Global Solutions, responsible for building integrated teams and working models that harness the collective marketing expertise of Stagwell's portfolio agencies in service of connected, scalable solutions for global clients. During his tenure at Stagwell, Napier has been key to the creation of a central client relationship management team that serves key global accounts. Amy Mayurnik has been tapped for the role of SVP, Global Recruitment, where she will lead and expand the network's central recruitment team in support of the growth underway across Stagwell's portfolio of companies. One of Stagwell's longest-serving employees with over a decade of experience in the network, Mayurnik has been instrumental in developing a global talent pipeline of over 250,000 leading creative, digital and technology-focused experts. Joining Mayurnik on the team - and doubling the size of Stagwell's central recruitment arm -- are Shane McEwen, Mariana Bustamante, and Doris Jones, with additional hires planned throughout 2022.

12:00 EST Bird Global falls -12.1% - Bird Global is down -12.1%, or -96c to $7.00.

12:00 EST Nam Tai Property falls -23.6% - Nam Tai Property is down -23.6%, or -$3.36 to $10.89.

12:00 EST Sonendo rises 17.0% - Sonendo is up 17.0%, or $1.41 to $9.69.

11:42 EST Roche completes repurchase of shares from Novartis - Roche (RHHBY) announced that it completed the repurchase of Roche shares that had been held by Novartis (NVS). On November 4, Roche and Novartis had announced this repurchase. In accordance with the respective resolution of the Extraordinary General Meeting of November 26, the 53,309,000 shares have now been repurchased by Roche and the corresponding consideration has been transferred to Novartis. The repurchased shares will be cancelled upon completion of the corresponding procedure. As previously announced, the transaction does not change the communicated outlook for the full year. Roche expects a mid-single-digit sales growth at constant exchange rates. Core EPS growth at constant exchange rates is targeted to be broadly in line with sales growth. Furthermore, Roche is aiming at increasing the dividend in Swiss francs also for 2021. Christoph Franz, Chairman of the Board of Directors of Roche, said: "With this transaction, we regain full strategic flexibility without compromising our operational scope of action. Rating agencies have confirmed the high quality of our ratings. On the basis of an unchanged dividend policy, all holders of Roche equity securities will benefit from the repurchase and the resolved capital reduction by cancellation of the repurchased shares and the earnings accretion resulting therefrom."

11:28 EST Longeveron Inc (Class A Stock) trading halted, volatility trading pause

11:03 EST Keysight, CTC advanced collaborate to test Wi-Fi 6E device - Keysight Technologies and CTC advanced GmbH have collaborated to certify the first Wi-Fi 6E device. The device, a broadband home gateway, was tested against the most recent version of the European Telecommunications Standard Institute standard EN 303 687, introduced to regulate usage of the new Wi-Fi frequencies, a mandatory procedure to gain market access.

10:55 EST Merck Canada announces expansion of manufacturing for molnupiravir - Merck (MRK) announced it has entered into an agreement with Thermo Fisher Scientific (TMO) to manufacture molnupiravir, Merck's investigational oral antiviral medicine for the treatment of COVID-19. This agreement is part of Merck's commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies. Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics. Thermo Fisher's manufacturing site in Whitby, Ontario, will manufacture molnupiravir for distribution in Canada and the United Kingdom as well as markets in the European Union, Asia Pacific and Latin America, pending local market approvals. It is one of three manufacturing sites in the world for this therapy. Merck also announced on December 3, 2021, that it has entered into a Supply Agreement with the Government of Canada for molnupiravir. Through this agreement, the Government of Canada has secured access to 500,000 patient courses, with options for up to 500,000 more in 2022.

10:33 EST Blackline Cold Storage selects Ryder to manage Port of Houston facility - Blackline Cold Storage announced it has chosen Ryder System to manage the warehouse operations for its new 298,000 sf, cold storage facility at the Port of Houston, TX. Blackline Cold Storage has chosen to align with Ryder to manage the facility's warehouse operations, scheduling, order fulfillment and distribution services at its Port of Houston location.

10:15 EST Immuneering Corporation (Class A Stock) trading resumes

10:05 EST Verizon appoints Krista Bourne as COO, Verizon Consumer Group - Verizon announced the appointment of Krista Bourne to the role of Verizon Consumer Group's COO, effective January 1, 2022. She will drive Verizon's market leadership in connected 5G experiences while continuing to transform VCG into a fully integrated technology company to capitalize on the next stage of growth. She will report to Manon Brouillette who was recently named incoming CEO of Verizon Consumer Group. In her most recent role as Senior Vice President & President of Consumer Sales and Operations, Bourne has been responsible for delivering all aspects of industry-leading wireless and wireline services through an omnichannel experience to more than 100 million customers nationwide.

10:02 EST Digital World reports receipt of 'fact-finding inquiries' from regulators - In a regulatory filing, Digital World Acquisition (DWAC) announced the company has received "certain preliminary, fact-finding inquiries from regulatory authorities," with which it says it is cooperating. "Specifically, in late October and in early November 2021, DWAC received a request for information from FINRA, surrounding events (specifically, a review of trading) that preceded the public announcement of the October 20, 2021 Merger Agreement. According to FINRA's request, the inquiry should not be construed as an indication that FINRA has determined that any violations of Nasdaq rules or federal securities laws have occurred, nor as a reflection upon the merits of the securities involved or upon any person who effected transactions in such securities. Additionally, in early November 2021, DWAC received a voluntary information and document request from the SEC which sought, inter alia, documents relating to meetings of DWAC's Board of Directors, policies and procedures relating to trading, the identification of banking, telephone, and email addresses, the identities of certain investors, and certain documents and communications between DWAC and TMTG. According to the SEC's request, the investigation does not mean that the SEC has concluded that anyone violated the law or that the SEC has a negative opinion of DWAC or any person, event, or security," the filing stated.

10:01 EST AIkido Pharma announces strategic interest in ASP Isotopes - AIkido Pharma announced that the company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. Anthony Hayes, CEO of AIkido, noted, "This clearly exemplifies another high growth opportunity for us with a potential monetization event in the first half of 2022. ASP's unique technology, large market opportunity, notable investors and well accomplished management team are what initially attracted us to this opportunity. Our strategic investment in ASP Isotopes is exciting as they may have the best solution to help solve the current supply chain issue of a potential supply side shock with their Aerodynamic Separation Process. The Mo-99 market is currently estimated to be valued at $3.8B per year but with nine out of ten facilities expected to close within 10 years many governments and companies are exploring alternative methods of producing MO-99. We remain focused on continuing to acquire assets in our space that we believe will create shareholder value and possible monetization in the next 6-9 months."

10:00 EST ProShares Bitcoin Strategy ETF falls -9.7% - ProShares Bitcoin Strategy ETF is down -9.7%, or -$3.29 to $30.60.

10:00 EST Cloopen rises 18.9% - Cloopen is up 18.9%, or 51c to $3.21.

10:00 EST Sunlands Online rises 23.4% - Sunlands Online is up 23.4%, or 75c to $3.95.

09:50 EST Trio Tech International trading resumes

09:47 EST Expro falls -9.0% - Expro is down -9.0%, or -$1.24 to $12.61.

09:47 EST ProShares Bitcoin Strategy ETF falls -9.5% - ProShares Bitcoin Strategy ETF is down -9.5%, or -$3.21 to $30.68.

09:47 EST Columbia Property rises 12.8% - Columbia Property is up 12.8%, or $2.19 to $19.25.

09:47 EST GCP Applied Technologies rises 14.5% - GCP Applied Technologies is up 14.5%, or $3.92 to $30.94.

09:40 EST Surface Oncology presents clinical data on SRF617 - Surface Oncology announced that new data from the ongoing Phase 1 study of SRF617, an antibody targeting CD39, will be presented in a scientific poster at the European Society for Medical Oncology Immuno-Oncology Congress, to be held virtually from December 8-11, 2021. The recommended Phase 2 dose for SRF617 monotherapy has been determined to be 1400 mg Q2W based on aggregate review of safety, clinical PK/PD and preclinical data. No instances of dose-limiting toxicity were observed through dose escalation to the 1400 mg dose level. PK are linear and correlate strongly with PD target occupancy. SRF617 is well-tolerated at doses that sustain full target occupancy throughout the dosing interval and demonstrate dose-dependent loss of CD39 on B cells. Early data from a patient undergoing paired tumor biopsy show marked decrease of CD39 expression in the tumor microenvironment following SRF617 treatment. Ten of 32 evaluable patients receiving SRF617 as a monotherapy had disease stabilization at eight weeks, with four persisting beyond 16 weeks. One patient with NSCLC whose disease previously progressed on chemotherapy and PD-1 blockade had prolonged disease stabilization beyond 24 weeks. The recommended Phase 2 dose for SRF617 in combination with pembrolizumab has also been determined to be 1400 mg Q2W. Of patients treated with SRF617 in combination with pembrolizumab, four of eight evaluable patients had disease stabilization at six weeks, with three of the eight exhibiting disease control at 12 weeks and one beyond 20 weeks. Of patients treated with SRF617 in combination with gemcitabine/albumin-bound paclitaxel, there was one confirmed partial response in a patient with pancreatic cancer whose disease had progressed on prior chemotherapy. The SRF617 1400mg dose cohort is currently enrolling.

09:38 EST Reata Pharmaceuticals trading resumes

09:35 EST Roche says CHMP recommends EU approval of Actemra/RoActemra for severe COVID-19 - Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended extending the marketing authorisation for Actemra/RoActemra to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future, Roche said.

09:33 EST BAE Systems selected by DoD for space circuit technology - BAE Systems has been selected by the Department of Defense, or DoD, to qualify a new generation of integrated circuit technology for use in the harsh environment of space. The new 12 nanometer technology uses a smaller feature size that provides a dramatic leap forward in space-based computing compared to current 45 nanometer technology.

09:32 EST Journey Medical Corp trading halted, volatility trading pause

09:26 EST Nano Dimension announces two sales of DragonFly IV 3D-AME systems - Nano Dimension announced that it has sold the first two DragonFly IV 3D-AME Printers, in addition to the two machines that have completed beta sites processes with other leading customers.

09:19 EST AST SpaceMobile pushing out target launch of BlueWalker 3 to Summer 2022 - AST SpaceMobile provided updated timing for the launch of its next satellite, BlueWalker 3, noting that as previously discussed on the Q3 2021 business update call and disclosed in its third quarter Form 10-Q, AST SpaceMobile had been evaluating whether to rebook the launch of BlueWalker 3 to target a new launch within months of the prior launch window of March 1, 2022 to April 30, 2022. On November 30, in accordance with the terms of the launch services agreement, AST SpaceMobile submitted a rebooking notice for a revised launch window targeting Summer 2022. "The ultimate launch timing is subject to mutual agreement and coordination with the launch services provider. The purpose for the rebooking of the BlueWalker 3 launch is to provide additional time for assembly, testing and final launch preparation," the company stated. AST SpaceMobile Founder, Chairman and CEO Abel Avellan, added: "Our technology development is on track and we have made significant progress on our BlueWalker 3 satellite, with a truly global effort from over 500 team members. BW3 is a 693-square-foot phased array designed to communicate directly with unmodified mobile phones from low Earth orbit, solving a huge gap in today's communications networks. We believe the updated launch window provides important and needed additional prep time to ensure a successful satellite launch."

09:19 EST Old Dominion November FY21 LTL revenue per day increased 29.9% YoY - Old Dominion Freight Line reported certain less-than-truckload operating metrics for November 2021. Revenue per day increased 29.9% as compared to November 2020 due to an 11.5% increase in LTL tons per day and an increase in LTL revenue per hundredweight. The change in LTL tons per day was attributable to a 15.2% increase in LTL shipments per day that was partially offset by a 3.2% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight excluding fuel surcharges increased 16.6% and 9.4%, respectively, as compared to the same period last year. Greg C. Gantt, President and Chief Executive Officer of Old Dominion, commented, "Our revenue growth through November reflects our continued ability to win market share and the ongoing strength in the domestic economy. We believe the sequential change in revenue per day for the fourth quarter of 2021 will once again exceed our 10-year average for this metric. We also expect that strong customer demand will continue into next year, as shippers continue to value our superior service and available network capacity at a time when the industry's capacity is generally limited. While we have capacity to support additional volume growth, we remain committed to further investment in our business to support our expectations for increased market share in 2022 and beyond. We are confident that the continued execution of our long-term strategic plan can produce long-term gains in market share and shareholder value."

09:18 EST Old Dominion November FY21 LTL revenue per day increased 29.9% YoY - Old Dominion Freight Line reported certain less-than-truckload operating metrics for November 2021. Revenue per day increased 29.9% as compared to November 2020 due to an 11.5% increase in LTL tons per day and an increase in LTL revenue per hundredweight. The change in LTL tons per day was attributable to a 15.2% increase in LTL shipments per day that was partially offset by a 3.2% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight excluding fuel surcharges increased 16.6% and 9.4%, respectively, as compared to the same period last year. Greg C. Gantt, President and Chief Executive Officer of Old Dominion, commented, "Our revenue growth through November reflects our continued ability to win market share and the ongoing strength in the domestic economy. We believe the sequential change in revenue per day for the fourth quarter of 2021 will once again exceed our 10-year average for this metric. We also expect that strong customer demand will continue into next year, as shippers continue to value our superior service and available network capacity at a time when the industry's capacity is generally limited. While we have capacity to support additional volume growth, we remain committed to further investment in our business to support our expectations for increased market share in 2022 and beyond. We are confident that the continued execution of our long-term strategic plan can produce long-term gains in market share and shareholder value."

09:16 EST Hawkins to acquire NAPCO Chemical, adding 3 branches in Texas - Hawkins has entered into a definitive agreement to acquire the assets of NAPCO Chemical Company and its affiliates. The transaction is expected to close by the end of December 2021. NAPCO Chemical manufactures and distributes water treatment chemicals from three locations in the cities of Spring, Lufkin, and Luling, Texas. "This acquisition demonstrates Hawkins' commitment to expand our footprint in the South and allows us to enter the Texas market. Upon completion of this acquisition, Hawkins will have 37 water treatment sites serving 26 states. I would like to reiterate our commitment to continue to grow our Water Treatment business and welcome the NAPCO team to the Hawkins organization and look forward to continued growth throughout the great state of Texas," said Hawkins Chief Executive Officer Patrick Hawkins. Manning, the current management team, and NAPCO Chemical's employees are expected to continue with the business. Hawkins expects that the acquisition will be accretive in its fiscal year 2023.

09:15 EST Vera Bradley, Warner Bros debuts new Harry Potter + Vera Bradley collection - Vera Bradley debuted the Harry Potter + Vera Bradley Luna's Medallion collection, a new limited-edition capsule collection in collaboration with Warner Bros. (T) Consumer Products. "We're celebrating the joy and excitement of the holiday season by once again collaborating with Warner Bros. Consumer Products to create another very special Harry Potter + Vera Bradley collection," noted Daren Hull, Vera Bradley Brand President. "Fans of the Wizarding World and Vera Bradley alike are sure to delight in the limited-edition Luna's Medallion collection, inspired by the one-of-a-kind, lovable Luna Lovegood"

09:12 EST Troika Media collaborates with Unimas on network rebrand - Troika Media Group announced that it has, in collaboration with Unimas, the American Spanish language television network owned by Univision Communications, completed a network rebrand to better reflect the evolution of the audience and content that make up Unimas today. It has been seven years since Troika and Unimas collaborated on the previous network rebrand. For 2021, the intent was to create an evolution of the existing brand. However, Unimas found that the audience and the programming had shifted significantly enough to warrant a completely new look and attitude. "Troika and Unimas set out to create a rebrand that would reflect the significant change to both. The result was a completely transformed visual identity, one that became current with the evolution of the channel and reconnects with the people and content that make up Unimas," the company said. "Unimas has been a valued client for many years, and we are delighted to be expanding our relationship and for being chosen as an integral partner in the transformation of its network brand. This new visual identity is in lockstep with a vibrant and thrilling brand," said Robert Machinist, Troika's Chairman and CEO.

09:11 EST Volcon received over 250 dealership applications, officially signed another six - Volcon announced that it has received over 250 dealership applications and has officially signed another six, totaling 25 secured tier-one brick-and-mortar stores since launching just three weeks ago. It also announced two new key hires in the newly formed Product Management department. Julio Vitti and Russ Whisler will immediately join the Austin-based team to develop Volcon's aggressive product roadmap and bring products to dealers nationwide and beyond.

09:10 EST Scilex Holdings, Vickers Vantage sign LOI for proposed business combination - Scilex Holding, a subsidiary of Sorrento Therapeutics, and Vickers Vantage Corp. I (VCKA), a Cayman Islands corporation, announced the signing of a letter of intent, LOI, for a proposed business combination. Scilex is dedicated to the development and commercialization of non-opioid pain management products for treatment of acute and chronic pain. Scilex's commercial product ZTLIDO 1.8%, a non-opioid prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia. SP-102 is the first non-opioid novel injectable corticosteroid gel formulation product in Phase 3 development for the treatment of lumbar radicular pain, containing no preservatives, surfactants, solvents, or particulates. Henry Ji, Chairman and Chief Executive Officer of Sorrento Therapeutics and Executive Chairperson of Scilex said, "If completed, this transaction could propel us into the next phase of growth, and we are excited to work towards partnering with a world-class group of investors at Vickers who recognize the opportunity for much needed change in the treatment of millions of patients suffering from acute and chronic pain worldwide." Terms of Letter of Intent: Completion of the proposed transaction is subject to the negotiation of a definitive merger agreement, approval by the SPAC's and Scilex's boards of directors, satisfaction of the conditions negotiated in the proposed Merger Agreement and approval of the proposed transaction by the SPAC's shareholders. The letter of intent contemplates the combined company changing its name to Scilex Holding Company and being led by Scilex's current management team. The letter of intent provides for gross proceeds of up to $140M, dependent on the level of SPAC shareholders that exercise redemption rights. Assuming execution of the proposed Merger Agreement and consummation of the proposed transaction, the Combined Company expects to capitalize on the commercialization of ZTlido 1.8%; SP-102, or SEMDEXA; SP-103 5.4%, or SP-103; and SP-104. Assuming the SPAC and Scilex enter into the proposed Merger Agreement, the parties will look to seek approval from the SPAC's shareholders in the first half of 2022.

09:08 EST Knight-Swift acquires MME in accretive purchase, that included $150M cash - Knight-Swift Transportation acquired 100% of RAC MME Holdings, and its subsidiaries, which operate under the brand names of Midwest Motor Express and Midnite Express together, "MME. Prior to the acquisition, MME's equity interests were held by an ownership group, including Red Arts Capital, Prudential Capital Partners, and Brightwood Capital Advisors. Founded over 100 years ago, MME provides less-than-truckload full truckload, and specialized and international logistics transportation services to a diverse customer base in its service territory in the upper midwestern and great northwestern regions of the United States. The MME regional footprint complements our current southeastern and midwestern LTL presence alongside our AAA Cooper Transportation brand, which together cover over half of the United States. The MME acquisition reflects progress on our ongoing commitment to building a nationwide LTL footprint, leading to the further diversification of our revenue streams. The transaction is expected to be 6c accretive to our Adjusted EPS1 in 2022. On a longer-term basis, we have identified potential areas of revenue and cost synergies that are expected to lead to growth and margin expansion consistent with our return-on-investment targets while preserving MME's brand, locations, people, and culture. MME is expected to generate approximately $137M in revenue, $27M in Adjusted EBITDA, and $16M in operating income for full-year 2021. MME serves its blue-chip customer list through a network of over 30 service centers with a door count of approximately 800, strategically located across the upper midwestern and great northwestern United States. Service is provided to customers in the United States, Puerto Rico, and Canada through affiliations with leading regional and national LTL companies. The MME fleet includes approximately 460 tractors and 930 trailers. MME has approximately 800 highly skilled and efficient associates and was ranked 26th on Transport Topics' list of top LTL carriers in 20212. The purchase price consideration included $150M in cash at the closing date of the transaction. The transaction was funded through cash-on-hand and borrowing on the Company's revolving credit facility.

09:07 EST OptimumBank Holdings announces entry into skilled nursing lending space - OptimumBank is excited to announce its entry into the skilled nursing lending space. Chairman Moishe Gubin is pleased to announce the approval of the Bank's first Senior Healthcare Facility loan as part of the Bank's updated strategic plan to address current and future financing needs of the Senior Healthcare Industry. Michael Blisko, who was elected to the Board of Directors at the 2021 Annual Meeting of Stockholders, possesses the professional abilities with a proven record of competence and accomplishments in the senior healthcare industry. Mr. Blisko is the CEO of Infinity Healthcare Management of Illinois and Infinity Healthcare Management of Indiana, healthcare consultancies that have agreements with facilities housing over 6,000 licensed skilled nursing beds in the following states: Illinois, Indiana, and Tennessee. Additionally, Mr. Michael Johnson recently joined OptimumBank as a member of its lending team. Mr. Johnson is a seasoned lender and has extensive commercial lending experience in the Senior Healthcare Industry, specifically with transactions associated with operating entity working capital lines, property entity acquisitions, re-finance and bridge to HUD loans in conjunction with the establishment of an appropriate treasury management setup. Avi Zwelling, who has been a Director of the Company and OptimumBank since December 2017, has done legal work for many skilled nursing facilities. Mr. Zwelling is the managing partner of Zwelling Law, PLLC which has offices in Boca Raton, Florida and Chicago, Illinois. Mr. Zwelling has been providing legal services to the Company and the Bank since 2012. The Bank plans to focus on smaller accounts receivable lines that current lenders in the space shy away from.

09:05 EST Nucor to build rebar micro mill in South Atlantic region - Nucor announced that the company's board of directors has approved the construction of a rebar micro mill, with spooling capabilities, to be located in the South Atlantic region. This will be Nucor's third rebar micro mill, joining its existing micro mills in Missouri and Florida, both of which began operations in 2020. The budgeted capex for the new micro mill is $350M. It will have an annual capacity of 430,000 tons.

09:05 EST Volaris reports November traffic up 41.7%, capacity up 28.8% - Load factor was up 8.0 p.p. Passengers were up 47%. All figures based on year over year comparisons.

09:03 EST Biofrontera enrolls first subject in Phase 1 safety study of PDT - Biofrontera announced that the first subject has been enrolled in a Phase 1 study to evaluate the safety and tolerability of photodynamic therapy for the treatment of actinic keratosis using three tubes of Ameluz together with the company's BF-RhodoLED XL lamp. This open-label study is being conducted at eight sites and will enroll 100 subjects with mild-to-severe AK on the face and scalp. The Phase 1 study follows a maximal-usage pharmacokinetics clinical study that was completed in early 2021. As announced in June, results from that PK study were presented to the U.S. Food and Drug Administration. The FDA subsequently requested another safety study focusing on transient adverse events before amending the product information, which currently limits use to one tube of Ameluz per treatment.

09:02 EST Astra announce launch for NASA in January - Astra announced that it plans to deploy its first satellite in orbit for the National Aeronautics and Space Administration, or NASA, in January 2022. The launch from Cape Canaveral will be conducted out of Space Launch Complex 46 and will be Astra's first launch out of Cape Canaveral.

08:56 EST Embraer's Eve, Sydney Seaplanes announce partnership - Eve Urban Air Mobility Solutions, an Embraer company, and Sydney Seaplanes announced a partnership that will lay the foundation for new electric air taxi operations in Greater Sydney. With the partnership, Sydney Seaplanes has placed an order for 50 of Eve's electric vertical takeoff and landing aircraft, with progressive deliveries expected to commence from 2026. The new partnership accelerates the progress towards 100% of greater Sydney's local tourism and commuter flights coming from zero emission electric aviation.

08:55 EST Vickers Vantage Corporation I trading halted, news pending

08:52 EST Axcelis announces successful completion of a Purion H high current evaluation - Axcelis Technologies announced the successful completion of a Purion H high current tool evaluation at "a leading advanced logic device manufacturer." The system will support high volume production of logic devices, the company stated. Executive Vice President, Product Development, Bill Bintz, commented, "We're very excited about the potential of this win, as we see significant opportunities for production buys in 2022 and 2023. The Purion H has an innovative high current implanter architecture, featuring unique scanned spot beam technology, designed for advanced memory and logic applications. The Purion H offers exceptional versatility, throughput and uniformity, enabling chip manufacturers to achieve greater yield with the lowest cost of ownership."

08:46 EST Kandi Technologies board authorizes share buyback up to $20M - Kandi Technologies Group announced that its Board of Directors has authorized the Company to repurchase up to $20 million of the Company's common stock. The plan authorizes purchases at management's discretion when the stock trades in a price range that the board believes represents a compelling use of cash. Kandi expects to commence the repurchase plan on December 10, 2021 and to conclude the plan by the end of 2022. Progress on the program will be disclosed each report on Form 10-K or Form 10-Q, as the case may be.

08:46 EST Goodfood Market launches on-demand delivery in Montreal - Goodfood Market has launched its on-demand quick delivery to key highly dense neighborhoods in Montreal. The service is available through the Company's new micro-fulfilment centre in the city's downtown and will deliver orders to customers in approximately 30 minutes. Goodfood also launched the delivery of alcohol in Toronto through its existing micro-fulfilment centre.

08:44 EST Neuronetics announces leadership role at Brain Stimulation Conference - Neuronetics announced their leadership role at the 4th International Brain Stimulation Conference December 6-9 in Charleston, South Carolina as the Platinum Sponsor of the conference. "We are honored to attend and participate in the 4th International Brain Stimulation Conference, an important meeting that takes a multidisciplinary approach to the science that is driving advances in this field," said Keith Sullivan, President and CEO of Neuronetics. "NeuroStar Advanced Therapy has pioneered the industry with breakthrough technology, using transcranial magnetic stimulation to treat major depressive disorder. Through our sponsorship, we demonstrate our continued commitment to furthering the scientific discussion and research around treatment and outcomes." NeuroStar data will be featured in a general session symposium entitled "What Can a Large TMS Registry Database Inform Us About Treatment Outcomes?"

08:43 EST Frontier Communications and YouTube TV announce partnership - Frontier Communications (FYBR) announced a partnership with YouTube TV (GOOG) that offers Frontier customers a streaming solution for live and on-demand video content that is flexible, innovative, and an amazing value. YouTube TV's subscription streaming service offers programming from 85+ top networks, including live and local sports, news, shows, movies, and more. Subscription comes with free unlimited cloud DVR storage space, personalized recommendations, and a family plan with six accounts per household. Starting Dec. 6 , Frontier customers can view content with a Smart TV, phone, tablet, computer, or other streaming devices. "This partnership with YouTube TV gives our customers the opportunity to cut the cord and still watch the live and on-demand content they love," said John Harrobin, Frontier's Executive Vice President of Consumer. "Customers can now enjoy our fiber-optic broadband service plus YouTube TV for the best price available in the market."

08:41 EST Post Holdings issues 2021 ESG report - Post Holdings released its 2021 Environmental, Social and Governance, ESG, report. The report details enterprise-wide sustainability accomplishments, as well as goals and commitments in the areas of greenhouse gas emissions, water stewardship, waste management, animal welfare and sustainable packaging and sourcing. The report also features information about Post's commitments to diversity, equity and inclusion, community engagement, governance and employee safety. "Post's ESG strategy is aimed at responding to both the moral and economic imperatives created by the impact we have on our environment and our goals with respect to how we treat each other," said Rob Vitale, President and Chief Executive Officer. "This report illustrates how our companies contribute to the overall purpose of serving our stakeholders while advancing our ESG journey."

08:41 EST Legend submits NDA to Japan regulator for BCMA CAR-T therapy Cilta-cel for RRMM - Legend Biotech (LEGN) announces submission of a New Drug Application, NDA, to the Japanese Ministry of Health, Labour and Welfare, MHLW, for ciltacabtagene autoleucel by its collaboration partner, Janssen Pharmaceutical (JNJ) . Cilta-cel is an investigational B-cell maturation antigen -directed chimeric antigen receptor CAR-T cell therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor , an immunomodulatory agent , and an anti-CD38 antibody. The submission is based on results from the Phase 1b/2 CARTITUDE-1 study conducted in the US and Japan, which evaluated the efficacy and safety of cilta-cel for patients with relapsed or refractory multiple myeloma.1 Cilta-cel is currently under regulatory review by several health authorities around the world, including the United States and Europe. "Today's submission is an encouraging step in our mission to provide a potentially transformative cell therapy option to patients with multiple myeloma," said Ying Huang, PhD, CEO and CFO of Legend Biotech. "We look forward to closely collaborating with our partner Janssen and the MHLW in order to make cilta-cel available to patients living with relapsed or refractory multiple myeloma, who have exhausted several standard-of-care treatments and are facing poor prognoses."

08:39 EST Osisko Gold announces purchase of additional royalties from Talisker - Osisko Gold Royalties is pleased to announce that it has entered into an agreement with Talisker Resources to acquire the following royalties for total cash consideration of C$7,500,000: an additional 0.5% net smelter return royalty on all minerals produced from the Bralorne property, increasing Osisko's total NSR royalty interest on Bralorne to 1.7%; a 1.5% NSR royalty on all minerals produced from the Ladner property which was recently acquired by Talisker through its purchase of New Carolin Gold Corp; and a future 1% NSR royalty on all minerals produced from the Golden Hornet property which becomes effective should Talisker exercise its option to acquire control of Golden Hornet. Bralorne is a large brownfields exploration property, covering an area of 13,782 hectares, located in south-central British Columbia that has produced over four million ounces of gold at an average grade of 17.7 g/t during its operating history. Talisker is currently conducting a 100,000 meter exploration drilling campaign at Bralorne which will serve as the basis for resource development and economic studies. The Ladner property was acquired by Talisker through its acquisition of New Carolin which was announced on July 26, 2021. The Ladner property comprises an area of 14,380 hectares of the Coquihalla Gold Belt in southern British Columbia. Like Bralorne, Ladner is a large property having excellent infrastructure and is accessible by a major provincial highway. Ladner also has a permitted 1,300 tonne per day mill and tailings facility. A technical report from 2015 conducted on Ladner, outlines a total inferred mineral resource of 691,540 ounces of gold. The Golden Hornet property comprises 4,959 hectares covering intrusion related gold vein systems. Previous work conducted on the property includes trench samples grading 21.1 g/t gold over 5.1 meters and 4.17 g/t gold over 14 meters. Talisker is currently conducting an initial drill campaign on Golden Hornet with results to be received in the coming months.

08:36 EST Columbia Financial board authorizes stock repurchase program up to 5M shares - Columbia Financial announced that the Company's Board of Directors has authorized a new stock repurchase program to acquire up to 5,000,000 shares, or approximately 4.6%, of the Company's currently issued and outstanding common stock, commencing upon the completion of the Company's existing stock repurchase program. The new stock repurchase program was adopted following the receipt of a notice of non-objection from the Federal Reserve Bank of Philadelphia. On February 1, 2021, the Company announced its third stock repurchase program which authorized the purchase of up to 5,000,000 shares. Under this previously announced program, 3,811,361 shares of common stock have been repurchased at a cost of $66.2 million, or $17.36 per share. As of November 30, 2021, there are 1,188,639 shares remaining to be repurchased under this existing program. The repurchase program permits shares to be repurchased in open market transactions or through privately negotiated transactions, and pursuant to a trading plan that the Company intends to adopt in accordance with Rule 10b5-1 of the Securities and Exchange Commission.

08:35 EST Mallard Acquisition receives Nasdaq notice regarding delayed quarterly report - Mallard Acquisition Corp. announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. As previously disclosed in the Current Report on Form 8-K filed on November 22, 2021 by the Company, in connection with the preparation of the Company's financial statements as of September 30, 2021, the Company's management, in consultation with its advisors, identified a classification error made in certain of its previously issued financial statements, arising from the manner in which, as of the closing of the Company's initial public offering, the Company valued its common stock subject to possible redemption. As a result of such classification error, the Company required additional time to prepare the Q3 Form 10-Q, and did not timely file the Q3 Form 10-Q. On December 6, 2021, the Company filed the Q3 Form 10-Q with the SEC. Accordingly, the Company believes that it has regained compliance with the Nasdaq rules.

08:35 EST Olink announces new publication on PEA technology - Olink Holding announced a new publication on Olink's PEA technology, providing an invaluable resource to the scientific community. "We are proud to share a recently published peer-review publication in Molecular and Cellular Proteomics. This is the first publication describing the details behind Olink's Explore platform, with Proximity Extension Assay technology coupled to readout using NGS," the company said. The article describes the technology, workflow and protocol for the method based on the already proven PEA technology in combination with NGS read-out. For many years, there has been a clear need and a growing demand for larger proteomic studies that can exploit the diagnostic potential held within the low abundant plasma proteome. "We are very proud to further develop our already commercialized technology with disruptive methods and use the already proven PEA technology in combination with NGS read-out which has led to an increased throughput. This advancement will have a major impact on the discovery of new biomarkers for disease prediction and prognosis and contribute to the development of the rapidly evolving fields of wellness monitoring and precision medicine," says Ida Grundberg, Chief Scientific Officer, of Olink Proteomics, one of the authors of the abstract.

08:33 EST Fastenal reports November sales up 18.9% to $524.17M - The company reported November sales of $524.17M versus $441.03M in the same month of last year. Fastenal reported November daily sales of $24.96M, up 13.2% versus 2020. Reference Link

08:33 EST Alexandria Real Estate raises quarterly dividend to $1.15 from $1.12 per share - The dividend is payable on January 14, 2022, to shareholders of record on December 31, 2021.

08:33 EST Safe-T announces deployment of ZTNA with three new customers - Safe-T Group announced that it has successfully deployed it's ZoneZero Trust Network Access, ZTNA, solution with several customers in India and South-East Asia. The deployments include multi-year service and support contracts. "We are very pleased to announce the deployment of our ZoneZero ZTNA solution to these new enterprise customers, especially as the selection of our solution follows a series of very intensive competitive testing and evaluation against several of the industry's most widely acclaimed products," stated Eitan Bremler, Co-Founder, VP Product Strategy and Marketing at Safe-T. "On behalf of Safe-T, I wish to thank our growing list of global channel partners who continue to leverage their local expertise and well-established customer networks to introduce Safe-T into the large ZTNA market, and look forward to further building upon the significant momentum we are seeing for our ZoneZero solution." After successfully demonstrating superior product performance and capabilities in a series of competitive evaluation programs, Safe-T's ZTNA solution was selected by new customers, including: Ramco Cements; Panacea Biotec; and A Regional Healthcare Facility Operator

08:31 EST H2O Innovation closes $55M credit facility with National Bank of Canada - H2O Innovation announced that it has entered into an agreement with National Bank of Canada to increase its revolving credit facility to $ 55 M. In addition, the term of this facility has been extended to December 1, 2024. The revolving facility is used to repay entirely the outstanding term loans with National Bank of Canada for an amount of approximately $14.5 M and the remaining amount is available for general corporate purposes such as working capital, permitted acquisitions and capital expenditures.

08:30 EST Superior Group acquires Sutter's Mill Specialties - BAMKO, the branded merchandise division of Superior Group of Companies, announced the acquisition of substantially all of the assets of Sutter's Mill Specialties of Tempe, Arizona. The transaction closed effective as of December 1, 2021. "The acquisition of Sutter's Mill is a major win for BAMKO. It immediately helps us extend the significant capabilities advantages we have over our industry competitors," said Jake Himelstein, President of BAMKO. "BAMKO is on a mission to continuously raise the ceiling of what it means to be the best company in our industry. Sutter's Mill's extensive in-house decoration, production, and engraving capabilities are second to none in this industry. We will immediately begin offering unique and custom capabilities to our entire customer base, making us a more capable and valuable partner in ways we can support their businesses." Himelstein went on to add that, "the first thing we look for in our acquisition targets is a cultural fit, and Michael Butler, the President of Sutter's Mill Specialties and his team have built something special that will fit so well with BAMKO's unique culture of growth, positivity, and competitive spirit."

08:28 EST Equity completes acquisition of three bank locations of Bank of Kansas City - Equity Bank, a subsidiary of Equity Bancshares, announced that it has completed its purchase and assumption agreement on December 3, 2021, acquiring the assets and assuming the deposits of three bank locations in St. Joseph, Missouri from Security Bank of Kansas City, a subsidiary of Valley View Bancshares of Overland Park, Kansas. Equity announced the entrance into the St. Joseph, Missouri market on July 19, 2021. "St. Joseph is an excellent fit for our growing Equity Bank network," said Brad Elliott, Chairman and CEO of Equity. "We're pleased to add bank locations to our Northern Missouri footprint, and we believe our local leadership and focus on our St. Joseph customers will appeal to a wide range of businesses and families in the region. Our strategy positions us to deliver hometown community banking in all of our locations with a sophisticated product and technology set, increased lending capacity, with the local dedication and expertise that regional customers trust," said Elliott. "Our customized business banking solutions and entrepreneurial focus appeal to growing business customers, and our innovative consumer products and commitment to community focus are great resources for our customers throughout our Equity footprint, including St. Joseph."

08:27 EST Middleby to acquire Kamado Joe and Masterbuilt for $385M in cash - The Middleby Corporation announced the acquisition of Masterbuilt Holdings with an estimated $250M in net sales for 2021. Headquartered in the Atlanta area, the brands are known for their outdoor residential products designed for cooking with charcoal. The purchase price of $385M will be funded in cash and financed under Middleby's existing senior credit facility. The transaction is expected to close in December 2021, subject to completion of closing conditions. "The residential outdoor market has gained momentum over the past few years as consumers are spending more time in the backyard. The addition of Kamado Joe and Masterbuilt expands our offerings in this large and growing category, complementing our Lynx, Viking, Josper and EVO residential outdoor cooking brands," said Tim FitzGerald, Middleby CEO. "Consumers are seeking products to enhance and simplify the backyard grilling experience. The Kamado Joe and Masterbuilt brands have grown rapidly as the company's new products have been adopted by the next generation of outdoor enthusiasts. Charcoal as an energy source for cooking continues to gain popularity due to its flavor profile, availability, and affordability. Kamado Joe and Masterbuilt are well positioned to capture the charcoal trend."

08:26 EST TFF Pharmaceuticals to host Science Day on December 13 - TFF Pharmaceuticals announced that it will host a science day related to two of the company's lead assets, inhaled voriconazole for invasive pulmonary aspergillosis and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30pm - 3:00pm Eastern Time. The webinar will feature presentations by Carsten Schwarz, MD, and Christopher Emig, Ph.D

08:25 EST China Xiangtai Food appoints Erick Rengifo as CSO, Jiaming Li as president - China Xiangtai Food announced the appointment of Dr. Erick W. Rengifo as Chief Strategy Officer and Director and Dr. Jiaming Li as new President to succeed Mr. Xiaohui Wu, who has resigned on December 6, 2021. Dr. Erick W. Rengifo is a Professor of Economics at Fordham University in New York. He is the founder of Terra Global Asset Management LLC, a registered investment advisor, and Terra Fintech LLC, a technology firm cataloged by the SEC as a large trader. Dr. Jiaming Li is the founder of MineOne Partners Limited, a crypto mining fund management company.

08:23 EST Identiv appoints Amir Khoshniyati as General Manager, VP, Transponder Business - Identiv announced Amir Khoshniyati as General Manager and Vice President, VP, Transponder Business. Khoshniyati is responsible for the company's global radio frequency identification technology solutions business. Khoshniyati joined Identiv in August 2021 as Vice President of Business Development, Americas.

08:21 EST IO Biotech announces third clinical collaboration with Merck for IO102-IO103 - IO Biotech (IOBT) announced that it has entered into a third clinical trial collaboration and supply agreement with Merck & Co. (MRK), through a subsidiary. The purpose of the collaboration is to evaluate IO Biotech's lead candidate, IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in previously untreated patients with three different tumor types- metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck (SCCHN), and metastatic urothelial bladder cancer, IO102-IO103 is an investigational novel immunotherapeutic agent designed to target the mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase and PD-L1. The planned Phase 2 trial will evaluate the safety and efficacy of the combination of IO102-IO103 with pembrolizumab in patients with previously untreated metastatic NSCLC, SCCHN, or UBC. Additional correlative endpoints will also be explored to elucidate the mechanism of action. Under the terms of the agreement, IO Biotech will sponsor the Phase 2 trial and Merck will supply pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.

08:20 EST Del Taco trading resumes

08:19 EST ConocoPhillips announces preliminary CapEx, return of capital plan, VROC - ConocoPhillips announced several updates that highlight the company's differentiated value proposition. This announcement follows the recent closing of the company's acquisition of Shell's Permian Basin properties on Dec. 1 for net cash of $8.6B. These announcement reflects the addition of Shell's Permian Basin properties, including the previously announced expected 2022 capital expenditures and production associated with that transaction. Highlights include: Planned companywide 2022 capital expenditures of ~$7.2B; The planned capital includes ~$0.2B for Scope 1 and 2 emissions-reduction projects across the company's global operations and investments in several early-stage low carbon technology opportunities to address end-use emissions; Expected 2022 annual average production of ~1.8 MMBOED, representing low single-digit percentage underlying growth versus pro forma 2021; Expected 2022 return of capital to shareholders of ~$7B, representing a ~16% increase versus 2021. The company is initiating a three-tier capital return program that will consist of a compelling ordinary dividend tier, a share repurchase tier, and a newly authorized quarterly variable return of cash, VROC tier. The first VROC of 20c per share will be paid on Jan. 14, to shareholders of record as of Jan. 3. ConocoPhillips CEO and Chairman Ryan Lance commented, "At mid-year, we presented a truly differential 10-year plan that embraced our Triple Mandate for how we will play a valued role in the energy transition: safely produce low cost of supply, low-GHG-intensity barrels to the market, deliver compelling financial and capital returns to investors, and meet a net-zero ambition. Today's announcement builds upon each element of the Triple Mandate and supports our belief that ConocoPhillips is the most durable, investable company in the E&P business. With the recent Permian acquisition, we're in an even stronger position to build upon our success in 2021 as we head into next year."...ConocoPhillips' preliminary 2022 capital expenditures budget and operating plan reflect an outlook for next year that is consistent with the company's June 2021 10-year plan, with the inclusion of the Permian acquisition and current estimates for inflation and non-operated activity. This plan honors the company's fundamental principles and capital allocation priorities and is expected to drive improvement in underlying cash from operations n support of growing returns of capital to shareholders. Additional details include: The planned ~$7.2 billion in 2022 capital expenditures includes $0.7 billion associated with the recent Permian transaction and are consistent on an underlying basis with the market update provided in June 2021. Although inflation and non-operated pressures have accelerated since that update, particularly in the Lower 48, the impacts of those factors have been mitigated by productivity improvements across our global, diverse asset base...As the company considers the business outlook, including forward commodity prices, it has set its expected 2022 capital returns to shareholders at ~$7 billion. This would represent a ~16% increase in returns of capital versus 2021 and is expected to be allocated roughly equally between cash and share repurchases across the three distribution tiers as follows: The first VROC payment of $0.20 per share is payable on Jan. 14, 2022, to shareholders of record as of Jan. 3. A VROC of approximately $1 billion subject to board review and approval, anticipated to be distributed ratably on a quarterly basis. The first VROC payment of $0.20 per share is payable on Jan. 14, 2022, to shareholders of record as of Jan. 3.

08:17 EST Sorrento publishes SARS-CoV-2 MPro inhibitors with potential to treat omicron - Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into host cells. SARS-CoV-2 main protease, or MPro, is a key enzyme for the viral life cycle including virus entry, replication and packaging. MPro is conserved in all discovered SARS CoV-2 variants and is identified as a target for developing broad-spectrum antiviral drugs. In addition, experimental evidence has shown that certain host proteases prime the SARS-CoV-2 spike protein for viral packaging, interactions with ACE2, and viral entry into the host. These include two serine proteases, furin and transmembrane protease serine 2, or TMPRSS2, and a cysteine protease cathepsin L. Small molecule medications that inhibit furin, TMPRSS2 and cathepsin L have shown efficacy in inhibiting SARS-CoV-2 replication. In the publication, a representative analog of the series, MPI8, demonstrated dual inhibition of MPro and cathepsin L with high potency and selectivity. Sorrento has collaborated with Professor Liu's lab at Texas A&M University to evaluate analogs in the series to develop an oral anti-COVID drug. An analog with features distinguished from current reported SARS-CoV-2 MPro inhibitors has been systematically evaluated and advanced to a late stage of pre-clinical phase.

08:15 EST UiPath, Qlik launch partnership for active intelligence, enterprise workflows - Qlik and UiPath announced their partnership and the launch of direct integration between Qlik Cloud analytics and the UiPath end-to-end enterprise automation software platform. The integration enables analytics users to leverage UiPath automations to drive action and prioritize tasks in downstream applications from directly within Qlik. The integration complements the automation that's already possible with Qlik Application Automation, and will help organizations in their journey to Active Intelligence, where technology and processes trigger immediate action from real-time, up-to-date and trusted data to accelerate business value across the entire data and analytics supply chain.

08:14 EST ICE COO Mark Wassersug to switch to CIO, Stuart Williams to succeed - Intercontinental Exchange announced a series of senior leadership changes across the company under CEO Jeff Sprecher. The following is a letter that Sprecher shared with the company's nearly 10,000 employees today: "All around us, the world is changing. The market environment in 2021 is vastly different than when we began our journey in 2000. At COP26, which concluded in Glasgow last month, the private sector pledged $130 trillion in finance commitments to address climate change, which provides great opportunity in many areas of our exchanges segment. Investors are seeking increased transparency in the fixed income markets, punctuated by a demand for more ESG data to guide investing in the $128 trillion bond market, an opportunity that's still in the early innings for our fixed income and data segment. The increasing cost of originating mortgages and changing regulatory framework are driving demand for increased efficiency and transparency in this space, trends that will continue to benefit our mortgage technology segment. I mention these factors that affect each of our businesses because at no point in our history have global trends and macroeconomic factors aligned so favorably with the strategic decisions that our management team have made over the past few years to prepare for them. ICE's ability to plan for such events has allowed it to thrive amid dramatic moments of change. And as times change, ICE is changing along with it. As I said in our third quarter earnings call a few weeks ago, our broad product and service platform positions us well to benefit from not only near-term cyclical events, but also longer-term secular growth trends. In the same way, the increasing expertise, experience, and diversity of our management team position us to innovate more rapidly, manage risk more efficiently, and grow more sustainably. As organizations everywhere adjust to a world transformed by the pandemic, our management team is evolving along with the market environment. I'm not going anywhere, but for many years, we've been working to develop the next generation of ICE leaders who'll bring energy and experience to drive our success in the future. Challenging this group of global leaders with new or expanded roles is fundamental to good governance and stewardship of our firm. Here are some of the noteworthy changes you'll see as we head into the new year: At the New York Stock Exchange, Sharon Bowen, an ICE and NYSE Board Member, one of the nation's leading finance and securities lawyers, and formerly a Commissioner of the Commodity Futures Trading Commission (CFTC), will become the next Chair of the NYSE. In addition, Lynn Martin, currently President, ICE Fixed Income and Data Services, has been appointed the next President of the NYSE, succeeding Stacey Cunningham, who is beginning a new chapter in her career and will join the Board of Directors of the NYSE. I'll share more thoughts on Stacey at the end of this note. Lynn will lead the NYSE with a knowledgeable, collaborative, and outstanding team of executives, including Michael Blaugrund, the Exchange's Chief Operating Officer, and John Tuttle, its Vice Chairman and Chief Commercial Officer. In addition, Hope Jarkowski, formerly the Co-head of Government Relations at ICE and currently the NYSE's Head of Equities, will become its General Counsel, replacing Elizabeth King who, you'll note below, is taking on additional ICE-wide responsibilities. While Lynn assumes her new role at 11 Wall Street, she will continue to serve as Chair of ICE Fixed Income and Data Services to help guide that business as Amanda Hindlian, currently the Global Head of Capital Markets at the NYSE, becomes its new President. The global business that Amanda will now lead includes our evaluated pricing business, which prices nearly 3 million securities daily, and our rapidly growing index business. As this business continues to expand, Mark Heckert, the Chief Product Officer of ICE Fixed Income and Data Services, will add leadership of the index and desktop areas of the segment as he broadens his duties. Turning to ICE as a whole, Mark Wassersug, ICE's Chief Operating Officer, will transition to a new role as the company's Chief Information Officer, overseeing our industry leading technology implementations across our growing business and working closely with Mayur Kapani, ICE's Chief Technology Officer. As Mark moves into this position, Stuart Williams will succeed him as Chief Operating Officer of ICE, reporting to ICE President Ben Jackson. Stuart, who is currently President of ICE Futures Europe, will remain in that post until a successor is identified and in place. As part of this transition of Stuart into a new role, Trabue Bland, currently President of ICE Futures U.S., will oversee all of ICE's Futures Exchanges, which will continue to report to Ben. Adding to Trabue's team, Jennifer Ilkiw, now the head of ICE Asia Pacific, will relocate to New York to serve as President of ICE Futures U.S. Rounding out the organizational changes, Elizabeth King, ICE's Chief Regulatory Officer, who will report to me, will add responsibilities for ICE ESG, our burgeoning product initiative around sustainable investing. Elizabeth will also oversee the NYSE's Board Advisory Council, which works with the CEOs of NYSE-listed firms to identify diverse candidates for boards of directors of venture-funded and newly public companies. In addition, Chris Edmonds, who also reports to me and has been leading our clearing businesses, will see his role expanding as Chief Development Officer for ICE, adding oversight of ICE's marketing and communications, in addition to his other duties..."

08:13 EST NV5 Global awarded $6M of geospatial task orders - NV5 Global announced that the US Geological Survey has awarded NV5 approximately $6 million of geospatial task orders under the Geospatial Product and Services Contract that was announced in September. These awards support three of USGS's primary mapping initiatives: the 3D Elevation Program, the Earth Mapping Resources Initiative, and the 3D Hydrography Program. Data collected and analyzed across these three initiatives is used to make critical decisions related to the environment, infrastructure, water resources, and natural resources. Under these task orders, NV5 will perform the geospatial collection and data processing of over 17,000 square miles of 3DEP lidar data and more than 92,000 line kilometers of airborne magnetic and radiometric geophysical data in support of EarthMRI in Southern California. NV5 will also deliver over 23,000 square miles of elevation-derived hydrographic mapping of five watersheds located in northern Alaska as part of 3DHP.

08:11 EST Arko Corp.'s GPM enters strategic partnership with Sbarro - GPM Investments announced a strategic partnership with Sbarro to launch new restaurants inside four Village Pantry store locations in Indiana. The first two stores are expected to open in December 2021, with two more locations expected to launch in early 2022. In participating locations, GPM will serve Sbarro's famous New York-style extra-large pizza slices handmade every day, with freshly prepared and stretched dough, hand shredded 100% whole milk mozzarella cheese, and San Marzano style tomatoes, with a variety of toppings, Stromboli, bread sticks, chicken wings, whole pizzas and chicken tenders. The partnership will enhance GPM's in-store experience and provide sought-after food offerings to customers, all while adapting to evolving consumer shopping habits. Earlier this year, GPM announced the completion of its second remodeled store in Mechanicsville, VA featuring a new deli, expanded grab 'n' go for prepared foods, and freezers for frozen foods. GPM also recently expanded its partnership with DoorDash to offer delivery in more than 600 stores, 84 of which now offer alcohol delivery.

08:10 EST Aemetis completes change of state of incorporation to Delaware - Aemetis announced that it has completed the reincorporation of the Company from the State of Nevada to the State of Delaware, including the filing of a December 1, 2021 amendment to the prospectus supplement dated August 18, 2021 solely to reflect the Reincorporation. The change in legal domicile was approved by an affirmative vote of the requisite holders of the Company's capital stock at the Company's Annual Meeting of Stockholders held on August 26, 2021. Common stock outstanding remained unchanged as a result of the Reincorporation. No additional shares of the Company's common stock were registered for sale in connection with the Amendment. As of December 3, 2021, the Company had 33,289,689 shares of common stock outstanding. Additionally, no changes have been made to the Board of Directors, management, business or operations of the Company as a result of the Reincorporation. The corporate headquarters will remain in Cupertino, California.

08:09 EST U.S. Navy awards SAIC $1.1B torpedo production contract - Science Applications International Corp has been awarded a $1.1B contract to produce, assemble, test and deliver the U.S. Navy's MK 48 MOD 7 Torpedo Afterbody Tailcones and MK29 Mod 0 Warshot Fuel Tanks. The AB/TC is the section of the torpedo containing propulsion and navigations systems, with 26 major sub-assemblies requiring the integration of greater than 500 pieces and parts in each. "SAIC is proud of our expanded work on integration, production, assembly, test and delivery contracts that support the MK 48 heavyweight torpedo system for the U.S. Navy," said Bob Genter, president of SAIC's Defense and Civilian Sector. "We are confident that our proven performance on the MK 48 will continue to provide the Navy with the sea-dominance weapon it requires." SAIC has extensive history in supporting the Navy's torpedo systems. This award builds on a previous contract from September 2016, which initiated production restart of the Afterbody Tailcone for the MK 48 Heavyweight Torpedo. In October 2020, SAIC was awarded a U.S. Navy contract for mission engineering and integration support to produce, test and deliver MK 29 Warshot and MK 28 Exercise Torpedo Fuel Tanks for the Naval Undersea Warfare Center Division Keyport. Additionally, in May 2020, the U.S. Navy awarded SAIC a contract for testing and data collection of MK 48 Heavyweight Torpedoes, and MK 54 and MK 46 Lightweight Torpedoes in support of the Naval Undersea Warfare Center Division Newport.

08:09 EST Vimeo appoints Eric Cox as CRO, Crystal Boyson as CPO - Vimeo (VMEO) announced the expansion of its leadership team with the addition of executives from across the SaaS industry, including creating two new senior executive roles to accelerate its growth and global expansion. Eric Cox has been appointed as Vimeo's first Chief Revenue Officer. A long-time leader at Adobe (ADBE), Cox most recently led Go-to-Market, Product Marketing and Sales for Adobe's Digital Media B2B business, focusing on Creative Cloud and Document Cloud. Crystal Boysen has been appointed as Vimeo's first Chief People Officer. Boysen joins Vimeo from Canva, where she was Global Head of People. Vimeo has recently added other seasoned executives to its Go-to-Market leadership, including Michael Schiff as head of Business Operations, and Erick Cruz as head of Customer Success, both previously at Salesforce.

08:07 EST Acurx says first patient enrolled in Phase 2b clinical trial of ibezapolstat - Acurx Pharmaceuticals announced that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022. C. difficile bacteria remains on the Centers for Disease Control and Prevention Urgent Threat list, highlighting the need for new therapeutics to treat CDI. Ibezapolstat is FDA QIDP and Fast Track Designated for priority review.

08:06 EST Seelos Therapeutics receives issued patent from Japanese Patent Office - Seelos Therapeutics announced that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION), covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein aggregation in Parkinson's disease.

08:05 EST MarketAxess reports November monthly trading volume of $653.4B - MarketAxess Holdings announced monthly trading volume for November 2021 of $653.4 billion consisting of $212.4 billion in credit volume and $440.9 billion in rates volume. November highlights included: Wider credit spreads and higher volatility in the second half of November led to increased trading activity on the platform; estimated U.S. high grade market share of 20.9%, up from 19.6% in October. Record monthly portfolio trading volume in November; quarter-to-date portfolio trading reached $10.3 billion, exceeding the full third quarter of $8.9 billion. U.S. Treasury bond volume of $432.7 billion, up 55% year-over-year; further adoption of the all-to-all Click-to-Trade protocol drove record investor client volume. Emerging markets trading volume up 14% year-over-year in November; November 2021 year-to-date EM trading volume already 7% higher than full year 2020. Estimated Eurobond market share of 13.3% up from 12.3% in October 2021 and 10.3% in November 2020; November 2021 year-to-date Eurobond trading volume already 6% higher than full year 2020. MarketAxess municipal bond volume grew 86% year-over-year to $2.2 billion; MuniBrokers platform volume of $6.5 billion.

08:04 EST Ventyx Biosciences announces first patient dosed in Phase 2 trial of VTX002 - Ventyx Biosciences announced that the first patient has been dosed in a Phase 2 randomized, placebo-controlled trial of VTX002 for the treatment of moderate-to-severe ulcerative colitis, UC. "Advancing VTX002 into a Phase 2 trial marks another significant milestone for Ventyx and speaks to the team's ongoing commitment to advance innovative new therapies for patients," said Raju Mohan, Chief Executive Officer of Ventyx. "Given the large addressable market for ulcerative colitis, we believe VTX002 has the potential to make a meaningful difference for the approximately one million patients in the United States afflicted by this disease." In a Phase 1 multiple ascending dose trial in healthy volunteers, VTX002 was well tolerated at all doses tested with no serious adverse events. In addition, VTX002 demonstrated a dose-dependent steady-state reduction in absolute lymphocyte count of up to 65%, which is a well-established biomarker for S1P1 receptor-mediated diseases. The Phase 2 trial is a randomized, placebo-controlled, clinical trial in moderate-to-severe UC patients. The trial design includes a 13-week induction treatment period followed by a 39-week open label extension with a primary efficacy endpoint of clinical remission at Week 13 as defined by the 3-Component Mayo Score.

08:03 EST BioPlus Acquisition announces pricing of upsized $200,000,000 IPO - BioPlus Acquisition announced that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market and will begin trading tomorrow, Friday, December 3, 2021, under the ticker symbol "BIOSU". Each unit consists one of the Company's Class A ordinary shares and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one of the Company's Class A ordinary shares at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "BIOS" and "BIOSW," respectively. The Company is a blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the life sciences industry. The Company is led by Chief Executive Officer and Chief Financial Officer, Ross Haghighat, and Chairman of the Board and Chief Business Officer, Jonathan Rigby. Cantor Fitzgerald & Co. is acting as the sole book running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

08:03 EST DoorDash introduces ultra-fast grocery delivery - DoorDash is introducing ultra-fast grocery deliveries in 10-15 minutes beginning with DashMart in New York City. With over 2,000 items, DashMart offers a wide assortment of fresh and frozen grocery staples, snacks, household goods, and local products to fulfill any last minute shopping needs - whether you forgot an ingredient for tonight's dinner, or don't have time to get more eggs and milk midweek. To start, ultra-fast deliveries will be offered from a new DashMart location in Chelsea, with more locations and partners coming over the next few months.

07:53 EST Axcella Health appoints Margaret Koziel chief medical officer - Axcella announced that Margaret Koziel has been promoted to the role of chief medical officer and added as a member of the company's executive team. Koziel, who previously served as VP, clinical development, joined Axcella in 2019, bringing a wealth of leadership experience within both biopharma and academia.

07:49 EST Ayr Wellness receives approval to being operations at Arizona facility - Ayr Wellness announced that it has received a Temporary Certificate of Occupancy, TCO, to begin operations in its Phoenix, Arizona cultivation facility. Jonathan Sandelman, Founder, Chairman and CEO of Ayr Wellness, said, "Ayr continues to execute on its plan for growth, with this Phoenix cultivation facility being the latest project to come online. Our talented cultivation team has already received great reviews for the Kynd premium flower being grown in our Chandler, Arizona facility, and we look forward to scaling production with this larger space. The flower produced will supply our three Oasis dispensaries, as well as our growing wholesale business in the state." The first crop was planted over the weekend, with its first harvest projected for mid-March 2022.

07:48 EST SL Green Realty annouces sale of 1080 Amsterdam Avenue for $42.5M - SL Green Realty, together with its joint venture partner, Stonehenge, announced the sale of its leasehold interest in 1080 Amsterdam Avenue for a gross sale price of $42.5 million resulting in a gain in excess of $15.0 million. The transaction is expected to close in January 2022, subject to customary closing conditions.

07:46 EST SL Green Realty signs 191,000 square foot expansion with Bloomberg - SL Green Realty announced that Bloomberg has signed a 191,207 square foot expansion lease at 919 Third Avenue covering the entire 28th through 33rd floors. This expansion increases Bloomberg's commitment at 919 Third Avenue to 748,415 square feet. In addition, at One Vanderbilt Avenue, SL Green signed a new 19,522 square foot lease with Flexpoint Ford, a private equity firm with a history of investing in the financial services and healthcare sectors, covering a portion of the 61st floor and a 6,554 square foot expansion lease with Stone Point Capital LLC covering a portion of the 50th floor. One Vanderbilt is now 92.7% leased. SL Green has signed 359,032 square feet of Manhattan office leases to date in the fourth quarter and 1,714,940 square feet of Manhattan office leases to date in 2021.

07:44 EST Arena Minerals announces increased investment by Lithium Americas - Arena Minerals announced the increased investment by Lithium Americas Corp. from approximately 12% to 17.5% of the issued and outstanding common shares of Arena. Lithium Americas has elected to exercise its right to appoint a member to the Board of Directors of Arena. Lithium Americas has nominated Mr. Ignacio Celorrio to join the Board. Mr. Celorrio is currently President, Latin America for Lithium Americas.

07:43 EST ECMOHO appoints Yuan Fang as independent director of the board - ECMOHO announced a change in its board of directors. Greg Ye tendered to the Board his resignation as an independent director of the Board, the chair and a member of the audit committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board for personal reasons, effective from December 1, 2021. Mr. Greg Ye's resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practice. The Board appointed Mr. Yuan Fang as an independent director of the Board, the chair and a member of the Audit Committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board, effective from December 1, 2021. Upon the effectiveness of Mr. Greg Ye's resignation and the appointment of Mr. Yuan Fang, the Board consisted of five directors, including two independent directors. As a foreign private issuer, the Company is permitted to rely on home country practice under the Nasdaq Stock Market Rules with respect to its board and committee composition. Yuan Fang has over 10 years of experiences in venture capital investment, operation management and investment banking. Mr. Yuan Fang joined Delta Capital in late 2014 and has been leading Delta Capital's investments in technology and consumer services areas.

07:41 EST Avicanna files patent for oral cannabinoid platform - Avicanna announced that it has filed a provisional patent application in the United States Patent and Trademark Office for a novel oral cannabinoid technology, which is intended to be commercialized globally for medical and pharmaceutical applications including treatment of various neurological diseases and disorders. Oral administration of cannabinoids is the most convenient route for non-invasive drug delivery. However, due to the highly lipophilic nature and poor water-solubility of cannabinoids the elementary formulations currently available on the market generally have poor bioavailability and lack consistent drug delivery. Avicanna's proprietary compositions have been specifically designed to alter the hydrophobic nature of cannabinoids, resulting in enhanced drug solubility which leads to better absorption and bioavailability either sublingually or orally, thereby increasing efficacy of cannabinoids. The patent application entitled "Oral cannabinoid compositions and methods of treating neurological diseases and disorders" claims formulations that have been developed through Avicanna's R&D platform utilizing the company's proprietary self-emulsifying drug delivery systems technology and include a range of drug delivery formats with varying release and absorption profiles including: Sustained and controlled release tablets - designed for linear release of the drug over time and thereby maximizing pharmacological properties and reducing side effects particular to cannabinoids. Oral capsules c self-emulsifying cannabinoid technology designed to enhance absorption through a fast and effective dispersion mechanism. Sublingual tablets - designed to provide rapid absorption of cannabinoids through the sublingual membrane to reduce first pass metabolism and provide a solution for acute symptom management and Water-soluble formulations - nano-emulsion technology designed for instant dispersion and dissolution of cannabinoids which can be utilized for convenient titration in drug delivery and beverages. Avicanna intends to conduct further pre-clinical studies in the coming months in order to formalize this provisional application and will incorporate the technology into its clinical pipeline in 2022. If granted, this patent application will provide Avicanna with protection on the use of the Formulation Candidates for neurological diseases, alone or in combination with other therapies.

07:39 EST Decibel Therapeutics appoints Alison Finger, Saraswathy Nochur to board - Decibel Therapeutics (DBTX) announced the appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors. Decibel also announced that Christine Poon has stepped down from the Board, effective December 3, 2021. Finger most recently served as Chief Commercial Officer at bluebird bio (BLUE). Dr. Nochur, who has been active in Boston's biotechnology industry since 1989, currently serves as Chief Diversity, Equity and Inclusion Officer at Alnylam Pharmaceuticals (ALNY).

07:38 EST Minim appoints Bill Wallace, Lakshmi Kadiyala as engineering VPs - Minim (MINM) welcomes two technology leaders to its team: Bill Wallace joins Minim as Vice President, Hardware Engineering from CommScope (COMM), and Lakshmi Kadiyala joins as Vice President, Software Engineering from Charles Schwab (SCHW). The team additions will join Alec Rooney, CTO of Minim, as the company pursues increased profitability through the introduction of advanced software-driven products in the coming year.

07:36 EST CloudMD graduates to the OTCQX - CloudMD Software & Services is pleased to announce that it has qualified to trade on the OTCQX Best Market. CloudMD begins trading today on OTCQX under the symbol "DOCRF". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

07:35 EST PROG Holdings comments on tender offer results; backs capital allocation - PROG Holdings commented on the preliminary results of its "modified Dutch auction" tender offer. The tender offer expired at 12:00 midnight, New York City time, at the end of the day on December 3. Based on the preliminary count by the Company's depositary agent, the Company expects to purchase approximately 13.2% of its outstanding shares at a price of $49.00 per share, for an aggregate cost of approximately $425M, excluding fees and expenses. "The expiration of our fully-subscribed $425M tender offer and last month's successful $600M senior note offering mark two major steps for PROG Holdings, as we implement capital allocation policies to support long-term growth and shareholder value creation as a high-growth, profitable and asset-light fintech company," said Steve Michaels, President and Chief Executive Officer of PROG Holdings. "With significant availability remaining under our $1B share repurchase program we announced last month, we are committed to continuing to buy back our shares while maintaining our ability to invest in growth and M&A, which remain our top priorities for long-term value creation." In connection with the expiration of the tender offer, the Company reaffirmed its capital allocation framework and priorities discussed during its third quarter earnings call, when management announced a new $1B share repurchase program authorized by the Company's Board of Directors. Under the new authorization, of which the tender offer was a first step, purchases can be made from time to time using a variety of methods, which may include open market purchases, purchases effected through 10b5-1 trading plans, accelerated share purchase programs, or other transactions.

07:34 EST Molecular Data adopts Blockchain to enhance its platform - Molecular Data has upgraded its platform using Blockchain for its current chemical business. With properties of Blockchain including traceability and transparency, such an adoption can be applied in numerous processes from the front to back end in the current business to improve credibility. Also, the transactions efficiency and safety will be enhanced.

07:33 EST Enveric Biosciences names Dr. Bob Dagher as Chief Medical Officer - Enveric Biosciences announced the appointment of Bob Dagher, MD, as Chief Medical Officer, effective immediately. Prior to joining Enveric, Dr. Dagher served as the Chief Medical Officer at WCG MedAvante-ProPhase.

07:33 EST Jack in the Box to acquire Del Taco for $12.51 per share in cash - Jack in the Box (JACK) and Del Taco (TACO) announced that the companies have entered into a definitive agreement pursuant to which Jack in the Box will acquire Del Taco for $12.51 per share in cash in a transaction valued at approximately $575M, including existing debt. While this price per share offers an attractive premium to Del Taco shareholders, Jack in the Box estimates that the transaction values Del Taco at a synergy adjusted multiple of approximately 7.6x trailing twelve months adjusted EBITDA. Jack in the Box expects the transaction to be mid-single-digit accretive to earnings per share excluding transaction expenses in year one and meaningfully accretive beginning in year two once full synergizes are realized. Jack in the Box expects the combined company to realize run-rate strategic and cost synergies of approximately $15M by the end of FY23, with approximately half of the synergies achieved in the first year. Jack in the Box expects to achieve these synergies largely through procurement and supply chain savings, technology and digital efficiencies and other financial benefits, as well as knowledge-sharing initiatives. Jack in the Box intends to finance the acquisition through the issuance of additional securitization notes from its existing program with a financing commitment provided by BofA Securities. The transaction is expected to close in the first calendar quarter of 2022 and is subject to customary closing conditions, including receipt of Del Taco shareholder approval and regulatory approvals.

07:32 EST Kforce announces Liberatore to succeed Dunkel as CEO - Kforce announced that Joseph Liberatore, the firm's current President, will succeed David Dunkel as Chief Executive Officer, CEO, effective January 1, 2022. Liberatore has been appointed to the Board effective immediately and will stand for election to the Board, as a Class I Director, at the Firm's annual meeting of shareholders in 2022. Dunkel has held the CEO position at Kforce and its predecessors for over 40 years. Dunkel will retire effective December 30, 2021 but remain employed by Kforce, on a limited, part-time basis and continue to serve as the Chairman of the Board of Directors.

07:28 EST Ranger Oil raises Q4 oil sales view 26,700-28,000 bbl/d - Ranger Oil Corporation announced an increase in the Company's oil sales guidance for the fourth quarter 2021 and updated its current hedge position. Darrin Henke, President and CEO of Ranger commented, "I am very pleased to announce that, due to the observed outperformance of existing wells, faster cycle times and less anticipated downtime, we now expect our fourth quarter sales volumes to be considerably higher than initially anticipated. As a result, we are positively revising as well as narrowing our guidance of anticipated sales volumes for the fourth quarter from a range of 25,700 - 27,700 barrels of oil per day, to a range of 26,700 - 28,000 bbl/d. Several factors are contributing to this outperformance, all of which we expect to continue in the future to drive best in class returns for our shareholders. First, our unwavering focus on increasing operating efficiencies resulted in decreased drilling and completion cycle times and accelerated turn-in-line dates for the quarter. In addition, of the wells recently turned-in-line, we continue to see initial outperformance relative to our forecasts as we optimize our completion and production designs, revealing the inherent quality of our acreage position. Third, we have seen very favorable initial results of our Lonestar integration efforts, resulting in the application of best practices on newly producing wells, such as deploying jet pumps for artificial lift. Lastly, the previously announced field infrastructure upgrades have largely been completed and at a faster pace than anticipated, resulting in less anticipated downtime, while also contributing to positive well performance. Given the continued operating efficiencies driving the revised guidance, the Company does not anticipate a change to its previously disclosed capital expenditure guidance of between $65 million and $75 million for the quarter. The use of commodity hedging is an integral part of the Company's risk management strategy. Given the attractiveness of recent markets, we continued to lean forward on our hedge strategy, resetting the acquired Lonestar hedges to at the market swaps upon closing in early October, as well as proactively placing additional hedge collars prior to the recent pull back in prices. Our collar levels placed quarter to date for the first half of 2022 have an average of approximately $63 per barrel downside protection, with an average upside exposure of $87 per barrel."

07:26 EST Del Taco trading halted, news pending

07:24 EST Power Solutions receives off-highway certification for low-emission 8.8L engine - Power Solutions International announced it received non-road certification for its 8.8-liter propane engine from the U.S. Environmental Protection Agency, EPA, and California Air Resources Board, CARB. The certification allows the propane-powered engine's use in mobile, non-road applications. The non-road certification allows PSI to bring the 8.8-liter engine to market for customers. Target applications include terminal tractors and other non-road mobile equipment for ports and other transport hubs. The non-road engine is part of PSI's efforts to expand its near-zero product line. This non-road engine shares the same technology as PSI's ultra-low NOx 8.8-liter propane engine previously approved for heavy-duty on-road applications.

07:23 EST ArcelorMittal receives shareholding notification from Societe Generale - ArcelorMittal (MT) announces that on 6 December 2021 it received a shareholding notification from Societe Generale (SCGLY). The notification was made to reflect Societe Generale SA's entry into various financial instruments. According to the notification, the following threshold of (potential) voting rights was reached: 5.03% on 1 December 2021

07:22 EST Diversey completes acquisition of Birko, Chad Equipment - Diversey Holding announced it has completed the acquisition of Birko Corporation, a North American manufacturer of food safety chemical solutions for the food and beverage industry, and Chad Equipment, a subsidiary of Birko Corporation, which manufactures food safety equipment for the protein industries. "This acquisition strengthens Diversey's market presence in the United States and Canada, enhancing its scale, service and product offering, and creating numerous cross-sell and revenue opportunities as a truly global provider in the food and beverage industries," the company said. Diversey's Chief Executive Officer, Phil Wieland commented, "We are truly excited to combine Birko and Chad's expertise with our North America food and beverage business. Closing this transaction is the first investment facilitated by our recent equity raise to accelerate growth and drive shareholder value. This acquisition is representative of our deep pipeline of growth investments and we will continue to pursue strategic and accretive M&A opportunities in the large, fragmented markets in which we operate. With this acquisition, we believe Diversey's food and beverage business now has the #1 or #2 market position in every region, which further enhances our ability to win business with global customers. Within the U.S., Birko and Chad's sales, service and manufacturing footprint will significantly improve our capability to serve customers, particularly in the central and western United States. Although the purchase agreement with the seller prohibits us from disclosing specific financials and deal terms, I can reiterate our M&A strategy is to acquire great businesses at 6x to 10x EBITDA with a medium term post-synergy multiple of 5x to 6x, and I can confirm this deal is consistent with that strategy."

07:19 EST Adicet Bio announces interim data from Phase 1 study of ADI-001 - Adicet Bio announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet's investigational therapy targeting CD20 for the potential treatment of B-cell Non-Hodgkin's Lymphoma. As of the November 22, 2021 data cutoff, six patients had been enrolled and received ADI-001. The first two patients enrolled in the lowest dose level tested did not reach the day 28 assessment and were not evaluable for efficacy per protocol. Three of the four evaluable patients achieved responses, including two complete responses, CR, and one partial response, PR, that investigators characterized as near complete response. "We are extremely excited to see such profound early complete responses in our Phase 1 dose-finding study evaluating ADI-001 as monotherapy among patients with very advanced cancer starting at our first dose level of 30 million CAR+ cells," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Data to-date suggest that ADI-001 is highly clinically active. We look forward to reporting additional data in the first half of 2022 and to rapidly progressing our pipeline to realize the full potential of our gamma delta CAR T cell platform for patients." Of the four efficacy evaluable patients, three received ADI-001 at dose level one and one received ADI-001 at dose level two. In dose level one, one patient achieved a CR, one patient achieved a PR that was characterized as near CR and one patient had progressive disease, PD. In dose level two, the first patient achieved a CR. All evaluable patients had been heavily pre-treated with a median of five lines of prior systemic therapies. Of the three patients who achieved PR or better under Lugano 2014 criteria, one had diffuse large B-cell lymphoma with five prior lines of therapy including two cycles of anti-CD19 CAR T cell therapy, one had follicular lymphoma transformed into a large B-cell tumor with four prior lines of therapy, and the third had mantle cell lymphoma with five prior lines of therapy. These patients achieved two CRs and a near CR. Overall, ADI-001 infusions were generally well-tolerated. No dose-limiting toxicities, graft vs host disease, Immune Effector Cell-Associated Neurotoxicity Syndrome or grade 3 or higher Cytokine Release Syndrome have been reported to-date, suggesting a potentially wide therapeutic window for ADI-001.

07:17 EST MediWound completes enrollment of EscharEx Phase 2 adaptive design study - MediWound announced it has completed patient enrollment in its U.S. Phase 2 adaptive design clinical study evaluating the safety and efficacy of EscharEx in debridement of venous leg ulcers, VLUs, compared to gel vehicle and non-surgical standard-of-care. "Completing enrollment in our U.S. phase 2 trial is an important step in advancing EscharEx as a non-surgical rapid and effective debridement agent with the potential to improve on the current standard of care for chronic wound management," said Sharon Malka, Chief Executive Officer of MediWound. "Chronic wound care is a significant market opportunity for us with an addressable market of over one billion dollars annually, and we believe EscharEx could be a meaningful part of that market. We look forward to sharing topline data from this study in the first quarter of 2022." The study is a multicenter, prospective, randomized, placebo-controlled, adaptive design study, evaluating the safety and efficacy of EscharEx in debridement of VLUs. The study enrolled 120 patients at approximately 20 clinical sites, primarily in the U.S. The primary endpoint is incidence of complete debridement compared to gel vehicle placebo control. Secondary endpoints include time to achieve complete debridement, reduction of pain, reduction of wound area, granulation tissue and quality of life. Incidence and time to achieve wound closure will be assessed as safety measurements. As part of the Company's broader EscharEx development program, MediWound is also conducting a phase 2 open-label, single arm study assessing the pharmacological effects of EscharEx in up to 15 patients with both diabetic foot ulcers and VLUs.

07:16 EST Fulcrum Therapeutics announces results from cohorts in Phase 1 trial of FTX-6058 - Fulcrum Therapeutics announced results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 clinical trial of FTX-6058. The company also shared new preclinical mechanism data showing that FTX-6058 downregulated known repressors of fetal hemoglobin. FTX-6058 is an investigational oral HbF inducer that is being developed for the treatment of sickle cell disease and other hemoglobinopathies, such as beta-thalassemia. Data from the 20mg and 30mg dose cohorts demonstrated a mean 5.6-fold induction and a mean 6.2-fold induction in HBG mRNA, respectively, at day 14. These increases were higher than those observed in the previously reported 2, 6 and 10mg dose cohorts. In preclinical studies of FTX-6058, increases in HBG mRNA have consistently translated to the same fold increases in HbF protein. Notably, human genetics show that 2-3-fold increases in HbF are associated with significantly improved outcomes, and even functional cures, in people with sickle cell disease. FTX-6058 has now demonstrated greater than a mean 2-fold induction starting with the 6mg dose. The Phase 1 randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetics of ascending doses of FTX-6058. In the single-ascending dose cohorts, healthy volunteers received one dose of either placebo or 2, 4, 10, 20, 30, 40 or 60mg of FTX-6058. In the multiple-ascending dose cohorts, healthy volunteers received a once-daily dose of placebo or 2, 6, 10, 20 or 30mg of FTX-6058 for 14 consecutive days. Each MAD cohort had six subjects on drug and two on placebo. Food effect was also studied in a separate 20mg dose cohort. Exploratory measures were included in the MAD cohorts to assess target engagement, as well as changes in HBG mRNA and HbF-containing reticulocytes. A 6mg dose cohort in people with sickle cell disease was recently added to this trial to further inform PK and pharmacodynamic modeling for future dose selection. All other cohorts in the trial have been completed, and data from the 2-40mg SAD cohorts and 2-10mg MAD cohorts were reported in August 2021. Consistent with the earlier reported data, FTX-6058 has been generally well-tolerated with no serious adverse events reported to date and there were no discontinuations due to treatment-emergent adverse events across all SAD and MAD cohorts. Across all cohorts, all TEAEs deemed possibly related to FTX-6058 were mild (Grade 1 or 2) and resolved. There was one Grade 4 TEAE in the 10mg MAD cohort and one Grade 3 TEAE in the food effect cohort, both of which were determined to be unrelated to FTX-6058. Data continued to show dose-proportional PK, with a mean half-life of approximately 6-7 hours in the MAD cohorts, supporting once-daily dosing, and no food effect was observed with FTX-6058. Data from the MAD cohorts continued to show robust target engagement, as evidenced by an approximately 75-95% reduction from baseline in H3K27me3 after 14 days of treatment. The data also showed higher-fold induction of HBG mRNA at the higher doses, with FTX-6058 achieving maximal rate of HBG mRNA induction in the 20mg and 30mg cohorts. Maximal HBG induction has not yet been achieved with the higher doses of FTX-6058. Persistent HBG mRNA induction was observed for 7-10 days after treatment. F-reticulocytes also increased by a mean of 1.8-fold in the 20mg cohort and a mean of 2.4-fold in the 30mg cohort as of the safety follow up visit, which was seven to 10 days after conclusion of dosing. Increases in F-reticulocytes of any magnitude are a first indicator that HBG mRNA is translating to HbF protein production, which Fulcrum anticipates observing in the Phase 1b trial that will dose people with sickle cell disease for up to three months. Fulcrum also announced new preclinical data demonstrating that FTX-6058 potently downregulated expression of BCL11A and MYB in multiple in vitro and in vivo models, suggesting that FTX-6058 may induce HbF protein production by silencing two validated master regulators of HbF induction. FTX-6058 achieved dose-dependent decreases in BCL11A and MYB expression. Further, FTX-6058's downregulation of BCL11A was correlated with both HBG mRNA induction and HbF induction, with a 2-3-fold increase in HbF when BCL11A expression was reduced greater than50%. Fulcrum is on track to initiate enrollment in the Phase 1b clinical trial of FTX-6058 by the end of 2021, with the aim of establishing early proof of concept in people with sickle cell disease. The open label trial is designed to assess safety, tolerability, PK and PD effects, including HbF protein induction, of up to three doses, starting with a 6 mg once daily dose, to inform dose selection for future development. Each dose cohort will have up to 10 patients who will be treated for up to three months. Fulcrum expects to report initial data from the trial in the second quarter of 2022 and plans to initiate a potentially pivotal Phase 2/3 trial in 2023. Additionally, Fulcrum plans to submit an Investigational New Drug application with the U.S. Food and Drug Administration by the end of 2021 to support the initiation of a clinical trial of FTX-6058 in additional hemoglobinopathies, including beta-thalassemia. As with sickle cell disease, genetic and clinical data suggest that elevated HbF levels may lead to better outcomes for people with other hemoglobinopathies.

07:15 EST Spectrum submits new drug application for poziotinib to FDA - Spectrum Pharmaceuticals announced that it has submitted its New Drug Application NDA for poziotinib to the U.S. Food and Drug Administration ( for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer with HER2 exon 20 insertion mutations. The NDA submission is based on the positive results of Cohort 2 from the ZENITH20 clinical trial, which assessed the safety and efficacy of poziotinib. The product has received Fast Track designation and there is currently no treatment specifically approved by the FDA for this indication. "The NDA submission for poziotinib marks an important step in achieving a first treatment for patients with HER2 exon 20 insertion mutations in lung cancer," said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. "I want to thank the patients, investigators and our internal staff who have passionately worked to achieve this important milestone in an area of high unmet medical need."

07:14 EST Li-Cycle appoints Debbie Simpson as CFO - Li-Cycle announced the appointment of Debbie Simpson to the role of CFO, effective February 1, 2022. Prior to joining Li-Cycle, Simpson served as the CFO of Maple Leaf Foods, a carbon neutral sustainable protein company with revenues of approximately $4B and over 13,000 employees. Simpson will succeed Li-Cycle's current CFO, Bruce MacInnis, upon his previously indicated retirement and the two will begin working together immediately to ensure a smooth transition and succession.

07:13 EST Autolus Therapeutics announces new time for investor call - Autolus Therapeutics announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology Annual Meeting & Exposition, being held between December 11-14, 2021. Management will host a conference call and webcast on Monday, December 13, 2021, at 8:00 am ET/1:00 pm GMT to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website.

07:12 EST Bausch Health receives AMPA seal of approval - Bausch Health announced Jublia Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association, or APMA, seal of approval.

07:10 EST Scynexis announces FDA agreement on strategy for approval of oral ibrexafungerp - SCYNEXIS announced initiation of a global Phase 3 study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a step-down therapy for patients with invasive candidiasis and/or candidemia following intravenous (echinocandin therapy in the hospital compared to currently-available outpatient therapies. The global Phase 3 multi-center, prospective, randomized, double-blind study of two treatment regimens will evaluate oral ibrexafungerp as a step-down treatment in patients suffering from invasive candidiasis compared to oral fluconazole. Eligible hospital patients with IC will receive treatment with IV echinocandin and will then be switched to either oral ibrexafungerp or oral fluconazole once step-down criteria are met. Approximately 220 patients will be enrolled and randomized in the study. The primary objective of the study is to determine whether treatment of IC with IV echinocandins followed by oral ibrexafungerp is as effective as treatment with IV echinocandins followed by oral fluconazole, the current standard of care. The primary end point of the study will be all-cause mortality at 30 days after initiation of antifungal therapy. There will also be an open label arm to evaluate oral ibrexafungerp compared to the best available therapy in patients with azole-resistant infections. Approximately 35,000 cases of IC in the U.S. per year are caused by Candida species that are resistant to azoles,1 for which ibrexafungerp could provide a much-needed oral alternative.

07:09 EST Zeta Global's Disqus, Akismet sign multi-year partnership to fight spam - Akismet, an anti-spam product developed by Automattic, is announcing a multi-year partnership with Disqus. Akismet will continue to protect Disqus' entire network-which includes sites like ABC News, Rotten Tomatoes, and The Hill-from spam, as it has since 2014. This multi-year partnership enables the companies to better fight spam and test out new cutting-edge features.

07:07 EST Laureate Education announced 58c per share special dividend - On Friday evening, Laureate Education announced that its board of directors approved, pursuant to the previously announced adoption of a plan of partial liquidation related to the distribution of net proceeds from the company's sale of Walden e-Learning LLC, the payment of a special cash distribution equal to $0.58 per each share of the company's Common Stock to each holder of record on December 14, 2021. The Distribution is scheduled to be paid on December 28, 2021. Based on the current number of shares outstanding, the aggregate amount of the Distribution is expected to be approximately $105M.

07:06 EST GH Research announces outcome of Phase 2 part of Phase 1/2 trial of GH001 - GH Research reported the successful outcome of the Phase 2 part of a Phase 1/2 clinical trial of GH001, an inhalable 5-MeO-DMT product candidate, in patients with treatment-resistant depression, TRD. The primary endpoint of the Phase 2 part of the trial was met with 7 of 8 patients in remission at day 7 after dosing. According to FDA Guidance for Industry, a 7-day endpoint is an appropriate primary efficacy endpoint for rapid-acting antidepressants. The Phase 2 part of the clinical trial recruited 8 patients. The median age was 34 years. The median baseline severity of depression by MADRS was 32. Patients followed a proprietary GH001 individualized dosing regimen administered on a single day with up to three increasing doses of GH001. The second and third doses were only administered in the event that the patient did not achieve a peak experience, PE, at the previously administered dose. Based on this trial design, 6 patients received 6 mg and 12 mg doses of GH001 and 2 patients received 6 mg, 12 mg and 18 mg doses of GH001. 7 patients were able to achieve a PE at their final dose, and at this final dose the mean PE total score was 90.4. Of the 7 patients who had a remission at day 7, all were in remission beginning on day 1, with 5 in remission as early as 2 hours after dosing. The single patient who did not achieve a remission at day 7, also improved on day 7 versus baseline. 6 of the 7 patients in remission had achieved a PE at their final dose. All patients completed all planned visits. No serious adverse events were reported. 7 of 8 patients experienced at least one adverse drug reaction, all of which were mild or moderate in intensity, and all of which resolved spontaneously. In addition, the company also reported positive preliminary safety results from a Phase 1 clinical pharmacology trial in healthy volunteers. This trial enrolled 46 healthy volunteers with 30-day safety follow-up. The trial investigated three different single doses of GH001. No SAEs were reported. 11 of 24 subjects who received GH001 in the single-dose part and 0 of 6 subjects who received placebo in the single-dose part experienced at least one ADR. In the multiple-dose part, 7 of 16 subjects who received GH001 experienced at least one ADR. All ADRs were mild and all ADRs resolved spontaneously.

07:06 EST Gritstone, CEPI expand vaccine agreement for omicron variant - Gritstone bio and CEPI, the Coalition for Epidemic Preparedness Innovations announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5M in additional funding to conduct a Phase 1 clinical trial of Gritstone's Omicron vaccine candidate in South Africa, where a CEPI-funded clinical trial of Gritstone's Beta variant COVID-19 vaccine is due to begin shortly. The SARS-CoV-2 T cell epitopes administered within Gritstone's SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platform's potential to address both Omicron and future variants of concern. CEPI is already funding up to $20.6M to support preclinical studies, manufacturing process optimization, and a Phase 1 trial of Gritstone's Beta variant vaccine candidate, which will be initiated by South Africa's University of the Witwatersrand in the coming weeks. The funding announced today will expand the Phase 1 trial to include additional arms to evaluate an Omicron-specific version of the vaccine. Gritstone has commenced manufacturing its SAM vaccine to specifically target the Omicron variant, and the Omicron arms of the Phase 1 trial are expected to begin in Q2 2022, subject to regulatory approval.

07:05 EST Else Nutrition establishes North American office in Ohio - ELSE NUTRITION HOLDINGS announces the establishment of a dedicated U.S. office and operations. Consistent strong growth of Else Nutrition product sales has led to the need for a full-time team on the ground in the U.S. In July of this year, Former Abbott Executive, Mike Glick joined Else Nutrition as General Manager and VP, North America. In his role within Else, Mike will oversee the rapidly growing Else Nutrition business across the US and Canada. A team is being actively built out, and Mike has selected Westerville, Ohio as the Headquarters location for North American operations. Else North America office is located at 501 W. Schrock Road, Westerville, Ohio with a team of 5 currently. Offering new team members a competitive remuneration package, the Company expects to double this in the coming year to keep up with the expected growth.

07:03 EST Catalyst Pharmaceuticals announces DyDo initiation of Phase 3 study of FIRDAPSE - Catalyst Pharmaceuticals announced that its collaboration partner DyDo Pharma has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome. Catalyst entered into a sub-license agreement with DyDo to develop and commercialize FIRDAPSE in Japan in June 2021. Under the terms of the agreement, Catalyst will provide clinical and commercial supply to DyDo and technical support to obtain regulatory approval for the product from the Japanese regulatory authorities. DyDo is responsible for the development and commercialization of the product in Japan pending regulatory approval, and Catalyst will be entitled to development and sales milestones and revenue for clinical and commercial supply of the product.

06:57 EST Broadridge appoints Dipti Kachru as global chief marketing officer - Broadridge announced the appointment of Dipti Kachru as global chief marketing officer, effective January 18. As Global CMO, Kachru will be responsible for leading all aspects of Broadridge's global marketing organization. She will focus on driving measurable growth, building Broadridge's global brand reputation, expanding client relationships, and supporting the organization's revenue growth ambitions. Kachru will be a member of Broadridge's executive leadership team, reporting to Chris Perry, president of Broadridge. She will be based in New York. Kachru joins Broadridge from J.P. Morgan where she most recently served as CMO for the Wealth Management division and can be credited for launching the J.P. Morgan Wealth Management brand and building an industry-leading client acquisition engine that delivered significant business growth.

06:55 EST The Buckle raises dividend 6.1%, announces $5.65 per share special dividend - The Buckle announced that at its quarterly meeting of the Board of Directors, held on December 3, 2021, the Board authorized a $5.65 per share special cash dividend to be paid to shareholders of record at the close of business on December 20, 2021. The Board also authorized a 35c per share quarterly dividend to be paid to shareholders of record at the close of business on December 20, 2021. This represents an increase of 2c per share, or 6.1%, in the company's quarterly dividend. Both the $5.65 per share special cash dividend and the 35c per share quarterly dividend, $6.00 per share in total, are payable on December 29, 2021 and will be paid together.

06:52 EST Rayonier Advanced Materials: Vito Consiglio to succeed Paul Boynton as CEO - Rayonier Advanced Materials (RYAM) announced that its Board of Directors elected Vito Consiglio to succeed Paul Boynton as President and CEO and Board member effective January 1, 2022. Boynton, who has served as President and CEO since the company's spin-off in 2014, announced his decision to retire from the company, and, as part of the leadership transition, he will assume the role of Vice Chair of the Board until the May 2022 Annual Meeting. Boynton plans to step down from his current executive duties in the new year after more than 10 years as CEO and Board member. He will serve as Vice Chair of the Board until the May 2022 Annual Meeting to facilitate a smooth transition. During the second half of 2022, Paul will support the company as a consultant. Consiglio most recently served as an advisor to multiple private equity firms on deals within the chemicals industry. Prior to that, Consiglio was with Ashland Global Holdings (ASH).

06:46 EST Advanced Drainage acquires Jet Polymer Recycling, terms not disclosed - Advanced Drainage Systems announced the acquisition of Jet Polymer Recycling, a privately-owned recycling company located in the southeastern region of the United States. Headquartered in Fort Payne, Alabama, Jet Polymer has three plastic recycling locations in Alabama and Georgia. Jet Polymer is currently the largest supplier of recycled polypropylene plastic for Infiltrator Water Technologies, a subsidiary of Advanced Drainage Systems.

06:43 EST Matinas BioPharma names Thomas Hoover as Chief Business Officer - Matinas BioPharma announced the appointment of Thomas Hoover to the newly created position of Chief Business Officer. Hoover's role will include business and corporate development, strategic planning, licensing, and alliance management. Thomas was most recently Chief Business Officer and Chief Commercial Officer at Millendo Therapeutics.

06:41 EST Crescent Point Energy sees FY22 capital expenditures $825M-$900M - Crescent Point Energy announced its 2022 capital expenditures budget and production guidance, another quarterly dividend increase beginning first quarter 2022, planned share repurchases and the renewal of its credit facilities. Crescent Point's 2022 capital expenditures budget of $825M to $900M is expected to generate annual average production of 133,000 to 137,000 boe/d. This production range represents an increase from the company's preliminary 2022 guidance of 131,000 to 135,000 boe/d and reflects the positive impact of Crescent Point's strong operational performance, primarily driven by its Kaybob Duvernay asset. The company's capital expenditures budget remains unchanged from its preliminary guidance. Crescent Point increased its cost inflation assumption for 2022, however, the assumed increase has been completely offset by well cost reductions recently realized in the Kaybob Duvernay. Consistent with its capital allocation framework, the company plans to allocate approximately 15% of its annual budget to long-term projects, including the advancement of various decline mitigation programs and environmental initiatives. Crescent Point's decline mitigation projects during 2022 include additional waterflood conversions, the expansion of its polymer floods and a pilot program to test carbon dioxide sequestration and enhanced oil recovery in Saskatchewan. The company's 2022 budget includes capital allocated to environmental projects designed to further reduce Crescent Point's overall emissions and inactive well inventory. The company's 2022 budget is focused, with approximately 90% of total development capital allocated to the Kaybob Duvernay, Viewfield, Shaunavon, Flat Lake and North Dakota plays.

06:39 EST GAP Airports reports preliminary November terminal traffic figures - Grupo Aeroportuario del Pacifico announces preliminary terminal passenger traffic figures for the month of November 2021, which includes comparisons with the 2019 and 2020 figures to facilitate the reading and understanding of the passenger traffic trend. For November 2021, the total number of terminal passengers at GAP's 12 Mexican airports increased by 3.7%, compared to the same period of 2019. Tijuana, Los Cabos and Puerto Vallarta airports presented an increase in passenger traffic of 19.2%, 16.2% and 7.8%, respectively, while the Guadalajara airport presented a decrease of 6.7%.

06:36 EST Aeglea BioTherapeutics announces PEACE trial meets primary endpoint - Aeglea BioTherapeutics announced that the pivotal Phase 3 study, PEACE, met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment with pegzilarginase. Importantly, pronounced and sustained plasma arginine reduction was accompanied by a positive trend in Gross Motor Function Measure Part E, or GMFM-E, a key clinical assessment of a patient's mobility, including the ability to walk, run and jump. PEACE is the first placebo-controlled clinical trial ever conducted in Arginase 1 Deficiency, or ARG1-D, and pegzilarginase is the first potential therapy to normalize the markedly elevated plasma arginine levels in these patients. Based on the results of this trial, Aeglea plans to submit a Biologics License Application, or BLA, to the FDA in the first half of 2022. Additionally, Aeglea will work with Immedica Pharma AB, its commercial partner in Europe and certain countries in the Middle East, to submit marketing authorization applications in those territories. PEACE is a global, randomized, double-blind, placebo-controlled trial that enrolled 32 patients with ARG1-D aged two years and older. The study was designed to assess the effects of treatment with pegzilarginase versus placebo from baseline through a prespecified 24-week treatment period. The primary endpoint assessed plasma arginine reduction from baseline levels. The key secondary endpoint evaluated mobility using GMFM-E, which consists of 24 tasks involving walking forward/backward, running, jumping and ascending/descending stairs, and the 2-Minute Walk Test, or 2MWT, a measure of the distance a patient walks in two minutes. Other secondary endpoints included additional outcome assessments, safety and pharmacokinetics. Topline results are summarized as follows: PEACE demonstrated a highly statistically significant 80% reduction in mean plasma arginine in pegzilarginase treated patients, the primary endpoint of the trial. Importantly, normal plasma arginine levels were achieved in 90.5% of pegzilarginase treated patients compared to none of the patients in the placebo arm. The least squares mean GMFM-E score improved by 4.2 units for pegzilarginase treated patients and worsened by 0.4 units in the placebo arm, establishing a positive trend in this mobility assessment. The least squares mean 2MWT distance increased 7.4 meters in pegzilarginase treated patients and 1.9 meters in the placebo arm. Pegzilarginase was well-tolerated and safety data were consistent with results from previous clinical trials. There were no study discontinuations due to adverse events. All 31 patients who completed the 24-week double-blind study period continued into the long-term extension, or LTE, portion of the PEACE trial. In addition, 13 of the 14 patients in the ongoing Phase 1/2 Open Label Extension, or OLE, trial have continued pegzilarginase therapy ranging from two to fout years. The previously presented 56-week data from the Phase 1/2 OLE trial supports the long-term clinical benefit of pegzilarginase treatment. The company believes that the entirety of data from the pegzilarginase program supports the long-term clinical benefit of pegzilarginase in ARG1-D. Additional data from the pegzilarginase program are expected to be presented at upcoming medical meetings and submitted to peer-reviewed medical journals.

06:34 EST Engine Capital urges Kohl's to separate ecommerce business, pursue sale - Engine Capital announced that it has sent a letter to Kohl's Board of Directors. The letter states, in part, "Given leadership's failure to create value through operational excellence and strategic initiatives over long periods of time, it is time for the Board to accept the fact that the public market is not appreciating Kohl's in its current form. Even the most patient long-term shareholders cannot be expected to endure the punishing underperformance and perpetual value disconnect seen at Kohl's. This is why we are urging the Board to publicly commit to conducting a full review of strategic alternatives. Our own analysis and interactions with an array of market participants lead us to believe there are two viable paths for the Board to explore: First, separating the legacy retail business and the ecommerce business so that the market can assign the proper valuation multiple to each business. The Board is hopefully aware that the public market is growing increasingly fond of simpler, more defined corporate structures. This is why an increasing number of large companies are spinning or splitting off assets that are best suited to operate as independent companies. As explained below, we believe a standalone Kohl's ecommerce business could be conservatively valued at $12.4 billion or more, an amount that dwarfs the company's current market capitalization. Second, given that the company trades at a massive discount to intrinsic value and its strategy has not resonated with the public market, we believe it is essential to run a market test to see how much well-capitalized financial sponsors would pay for the entire company. Our own diligence leads us to believe there are financial sponsors who will be able to pay a significant premium of 50%, or at least $75 per share."

06:26 EST Lucid Group drops 11% to $41.88 after announcing receipt of subpoena from SEC

06:16 EST Lucid Group says received subpoena from SEC on December 3 - On December 3, Lucid Group received a subpoena from the SEC requesting the production of certain documents related to an investigation by the SEC. Although there is no assurance as to the scope or outcome of this matter, the investigation appears to concern the business combination between the company and Atieva, Inc. and certain projections and statements. The company is cooperating fully with the SEC in its review.

06:05 EST ReneSola announces $50M share repurchase program - ReneSola announced that its board of directors has authorized the repurchase of up to $50M of the company's outstanding American Depositary Shares, or ADS. The authorization is effective immediately and has no expiration. As of this date, the company had approximately 70M ADS outstanding.

06:03 EST Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial - Bolt Biotherapeutics announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, the company's lead immune-stimulating antibody conjugate in a poster session at the European Society for Medical Oncology Immuno-Oncology Congress 2021, being held virtually from Dec. 6-11, 2021. The lead author for the poster is Manish Sharma, M.D., START Midwest, with contributions from Ecaterina Dumbrava, M.D., MD Anderson Cancer Center, and other colleagues from the U.S. and South Korea. The company reported data from 57 subjects participating in an ongoing Phase 1/2 study of BDC-1001, across 16 different types of HER2-expressing solid tumors. BDC-1001 demonstrated a favorable safety and tolerability profile at all evaluated doses and schedules, showing early signs of clinical activity with corresponding biomarker changes in the tumor microenvironment of post-treatment tumor biopsies. BDC-1001 is an immune-stimulating antibody conjugate comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to an innovative TLR7/8 agonist.

05:38 EST Teck provides update on sales, production guidance after severe weather in B.C. - Teck Resources provided an update to sales and production guidance, related to logistics disruptions caused by heavy rain, flooding and mudslides in British Columbia, Canada. The company said, "Rail service between west coast terminals and Teck's B.C. operations remains impacted by recent heavy rains and flooding, with both CN and CP operating at reduced levels following service interruptions. As a result of the rail disruption, primarily affecting shipments to Neptune and Westshore terminals in the Lower Mainland, we now estimate our fourth quarter steelmaking coal sales at 5.2 - 5.7 million tonnes, compared to 6.4 - 6.8 million tonnes previously. We have diverted shipments to Ridley Terminals in Prince Rupert to maximize sales during the quarter, which will affect our transportation costs for the quarter. CN and CP are reporting positive progress on restoring service capacity and are continuing to increase Teck shipments to Lower Mainland terminals. We expect that when rail service is fully restored we will be able to substantially recover delayed fourth quarter sales in the first half of 2022. Strong logistics chain performance leading up to the heavy rain events resulted in historically low clean coal inventories at our operations, mitigating impacts on production volumes. To date, we have not idled any processing facilities and continue to stockpile clean coal at sites and manage available railing capacity to minimize production impacts. As a result, we expect annual steelmaking coal production of 24.5 - 25.0 million tonnes, compared to our previous guidance following the wildfires in the third quarter of nearly 25 million tonnes. We now estimate our 2021 annual adjusted site cash cost of sales to be approximately $64 - $66 per tonne, slightly above the upper end of our previous guidance of $59 - $64 per tonne. Due to the ongoing rain-related rail disruptions and associated demurrage costs in the fourth quarter, in addition to previously disclosed wildfire impacts and inflationary pressures, we now expect 2021 full year transportation costs of $44 - $46 per tonne compared to our previous guidance of $42 per tonne or slightly higher for the year. We note that increased costs are more than offset by continued strong steelmaking coal prices through the second half of 2021. The average steelmaking coal price for the three months ending November 30, 2021 settled at US$371 per tonne, US$168 higher per tonne on an FOB basis than the three month average at end of August 2021, and US$254 higher than the three month average at the end of May 2021, compared to only $3 per tonne higher transportation cost, based on the mid-point of our updated annual guidance. While there has been no impact to production at Highland Valley Copper, up to 4,500 tonnes contained copper in concentrate sales are also at risk of being delayed into the first quarter of 2022 due to logistics chain disruptions."

05:24 EST Molecular Partners presents results from ensovibep study for COVID-19 patients - Molecular Partners announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients as well as additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza, or ESWI, Conference. The single arm Phase 2a study enrolled 12 patients, all of whom were confirmed as positive for COVID-19 with mild to moderate symptoms. The single center study was designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep. The results were presented by study investigator Johan van der Plas from the Centre for Human Drug Research, or CHDR, Leiden, the Netherlands. First ensovibep data from COVID-19 infected patients: 225 mg and 600 mg doses were seen to be safe and well tolerated. No disease enhancement, infusion related reactions, or dose limiting toxicities observed. Viral load data showed a comparable decline for both dose levels. Infectivity of virus extracted through nasopharyngeal swabs was reduced to zero within three to five days post treatment in patients with positive titers at baseline. Favorable PK profile in patients consistent with the profile observed in healthy volunteers. Confirmation of half-life and prolonged therapeutic exposure greater than2 weeks in all dosed patients. Complete COVID-19 clinical symptom recovery in the study population. These findings support large-scale controlled evaluation of ensovibep as a treatment for mild-to-moderate COVID-19. Molecular Partners also presented additional data from the Phase 1, randomized, double-blind, placebo-controlled single ascending dose study for safety, tolerability, and pharmacokinetics of intravenously administered ensovibep, which indicated that it was well tolerated with a half-life in the range of 2-3 weeks.

05:07 EST Volta expands into European market - Volta announced its expansion into the European market, with an initial focus on Germany, Austria, Switzerland, and France. The announcement was made at the NOAH Conference in Zurich.

05:05 EST Daqo New Energy begins pilot production at new polysilicon production facility - Daqo New Energy announced that it had completed the construction ahead of schedule and begun pilot production at its new 35,000 MT Phase 4B polysilicon production facility. The company expects its Phase 4B polysilicon production facility to gradually ramp up to full production capacity and to increase its total annual production capacity to 105,000 MT by the end of Q1 of 2022. Longgen Zhang, CEO of Daqo New Energy, commented, "We are very excited to have completed the construction in our new Phase 4B polysilicon production facility. We have already successfully harvested the first batch of polysilicon produced in the new facility. It is a great achievement for us to complete the project ahead of schedule given the significant difficulties and challenges resulting from the resurgence of COVID-19. This would not have been possible without the dedication and expertise of our outstanding team and various suppliers who have set up a new benchmark of excellence for the Company and the industry. We expect to ramp up the new Phase 4B facility to full capacity by the end of March 2022."